

CHEST Physician®

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS



Palliative care practitioners can provide comprehensive management of symptoms beyond those limited to the lungs.

SDI Productions/E+/Getty Images

Palliative care specialists seek greater role in lung disease

BY RANDY DOTINGA
MDedge News

Mrs. S's long-term chronic obstructive pulmonary disease (COPD) prognosis was grim, and she faced a harder time getting through each day. But neither she nor her primary care physician was willing to embrace strategies other than drugs.

"She felt guilty for continuing to smoke, but also expressed a need to smoke to help her deal with her husband's cancer and eventual death," recalled Georgia Narsavage, PhD, RN, ANP-BC, professor emerita of nursing at West Virginia University. "Her primary care physician was reluctant to introduce any treatment other than

medications because her family was resistant to facing 'mother dying.'"

But things changed when Mrs. S. was referred to a palliative care clinical nurse specialist following a hospitalization. "The goal of palliative care is to support quality of life by relieving symptoms and decreasing suffering. She was assisted to improve functioning overall, and home support services were provided," Dr. Narsavage said. "They allowed her to live at home relatively pain free with decreased dyspnea for 3 more years until her transition to hospice care a few months before death.

It wasn't quite a happy ending. But it was a happier ending, and one that palliative care (PC)

PALLIATIVE CARE // continued on page 6

Coronavirus can spread to heart, brain days after infection

BY CAROLYN CRIST

The coronavirus that causes COVID-19 can spread to the heart and brain within days of infection and can survive for months in organs, according to a new study by the National Institutes of Health.

The virus can spread to almost every organ system in the body, which could contribute to the ongoing symptoms seen in "long COVID" patients, the study authors wrote. The study is considered one of the most comprehensive reviews of how the virus replicates in human cells and persists in the human body. It is under review for publication in the journal Nature (2021 Dec 20. doi: 10.21203/rs.3.rs-1139035/v1).

"This is remarkably important work," Ziyad Al-Aly, MD, director of the Clinical Epidemiology Center at the Veterans Affairs St. Louis Health Care System, told Bloomberg News. Dr. Al-Aly wasn't involved with the NIH study but has researched the long-term effects of COVID-19.

"For a long time now, we have been scratching our heads and asking why long COVID seems

CORONAVIRUS // continued on page 7

INSIDE HIGHLIGHT



NEWS FROM CHEST

Pulmonary Perspectives®

Dr. Aaron Holley tackles ICS for COVID-19

Page 20

Follow CHEST 2022 to Music City
It's time to write a new song

NASHVILLE CHEST 2022
OCT. 16-19

LEARN MORE AT chestmeeting.chestnet.org

PERMIT 500
HARRISBURG PA
PAID
U.S. POSTAGE
PSRT STD

CHANGE SERVICE REQUESTED

CHEST PHYSICIAN
10255 W Higgins Road,
Suite 280
Rosemont, IL 60018

Nucala 
(mepolizumab)
Injection 100 mg/mL

The targeted therapy for 4 eosinophil-driven diseases

**Severe
eosinophilic
asthma (SEA)**

**Chronic rhinosinusitis
with nasal polyps
(CRSwNP)**

**Eosinophilic
granulomatosis with
polyangiitis (EGPA)**

**Hypereosinophilic
syndrome (HES)**

NUCALA is for the:

- add-on maintenance treatment of patients 6+ with SEA. Not for acute bronchospasm or status asthmaticus.
- add-on maintenance treatment of CRSwNP in patients 18+ with inadequate response to nasal corticosteroids.
- treatment of adult patients with EGPA.
- treatment of patients aged 12+ with HES for ≥ 6 months without an identifiable non-hematologic secondary cause.

Important Safety Information

CONTRAINDICATIONS

NUCALA should not be administered to patients with a history of hypersensitivity to mepolizumab or excipients in the formulation.

Please see Brief Summary of Prescribing Information for NUCALA on the following pages.



Visit [Nucala4EOS.com](https://www.nucala4eos.com) to learn more →

Important Safety Information (cont'd)

WARNINGS AND PRECAUTIONS

Hypersensitivity Reactions

Hypersensitivity reactions (eg, anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred with NUCALA. These reactions generally occur within hours of administration but can have a delayed onset (ie, days). If a hypersensitivity reaction occurs, discontinue NUCALA.

Acute Asthma Symptoms or Deteriorating Disease

NUCALA should not be used to treat acute asthma symptoms, acute exacerbations, or acute bronchospasm.

Opportunistic Infections: Herpes Zoster

Herpes zoster infections have occurred in patients receiving NUCALA. Consider vaccination if medically appropriate.

Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids abruptly upon initiation of therapy with NUCALA. Decreases in corticosteroid doses, if appropriate, should be gradual and under the direct supervision of a physician. Reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Parasitic (Helminth) Infection

Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving NUCALA and do not respond to anti-helminth treatment, discontinue NUCALA until infection resolves.

ADVERSE REACTIONS

Most common adverse reactions ($\geq 5\%$) in patients receiving NUCALA:

- Severe asthma trials: headache, injection site reaction, back pain, fatigue
- CRSwNP trial: oropharyngeal pain, arthralgia
- EGPA and HES trials (300 mg of NUCALA): no additional adverse reactions were identified to those reported in severe asthma clinical trials

Systemic reactions, including hypersensitivity, occurred in clinical trials in patients receiving NUCALA. Manifestations included rash, pruritus, headache, myalgia, flushing, urticaria, erythema, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, stridor, angioedema, and multifocal skin reaction. A majority of systemic reactions were experienced the day of dosing.

USE IN SPECIFIC POPULATIONS

A pregnancy exposure registry monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy. To enroll call 1-877-311-8972 or visit www.mothersbaby.org/asthma.

The data on pregnancy exposures are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as the pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimesters.

Trademarks are owned by or licensed to the GSK group of companies.



©2021 GSK or licensor.
MPLJRNA210003 December 2021
Produced in USA.

BRIEF SUMMARY

NUCALA (mepolizumab) for injection, for subcutaneous use NUCALA (mepolizumab) injection, for subcutaneous use

The following is a brief summary only; see full prescribing information for complete product information.

1 INDICATIONS AND USAGE

1.1 Maintenance Treatment of Severe Asthma

NUCALA is indicated for the add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype [see Use in Specific Populations (8.4) and Clinical Studies (14.1) of full prescribing information].

Limitations of Use

NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus.

1.2 Maintenance Treatment of Chronic Rhinosinusitis with Nasal Polyps

NUCALA is indicated for the add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.

1.3 Eosinophilic Granulomatosis with Polyangiitis

NUCALA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis (EGPA).

1.4 Hypereosinophilic Syndrome

NUCALA is indicated for the treatment of adult and pediatric patients aged 12 years and older with hypereosinophilic syndrome (HES) for ≥6 months without an identifiable non-hematologic secondary cause.

4 CONTRAINDICATIONS

NUCALA is contraindicated in patients with a history of hypersensitivity to mepolizumab or excipients in the formulation [see Warnings and Precautions (5.1) and Description (11) of full prescribing information].

5 WARNINGS AND PRECAUTIONS

5.1 Hypersensitivity Reactions

Hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred following administration of NUCALA. These reactions generally occur within hours of administration, but in some instances can have a delayed onset (i.e., days). In the event of a hypersensitivity reaction, NUCALA should be discontinued [see Contraindications (4)].

5.2 Acute Asthma Symptoms or Deteriorating Disease

NUCALA should not be used to treat acute asthma symptoms or acute exacerbations. Do not use NUCALA to treat acute bronchospasm or status asthmaticus. Patients should seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.

5.3 Opportunistic Infections: Herpes Zoster

Herpes zoster has occurred in subjects receiving NUCALA 100 mg in controlled clinical trials [see Adverse Reactions (6.1)]. Consider vaccination if medically appropriate.

5.4 Reduction of Corticosteroid Dosage

Do not discontinue systemic or inhaled corticosteroids (ICS) abruptly upon initiation of therapy with NUCALA. Reductions in corticosteroid dosage, if appropriate, should be gradual and performed under the direct supervision of a physician. Reduction in corticosteroid dosage may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

5.5 Parasitic (Helminth) Infection

Eosinophils may be involved in the immunological response to some helminth infections. Patients with known parasitic infections were excluded from participation in clinical trials. It is unknown if NUCALA will influence a patient's response against parasitic infections. Treat patients with pre-existing helminth infections before initiating therapy with NUCALA. If patients become infected while receiving treatment with NUCALA and do not respond to anti-helminth treatment, discontinue treatment with NUCALA until infection resolves.

6 ADVERSE REACTIONS

The following adverse reactions are described in greater detail in other sections:

- Hypersensitivity reactions [see Warnings and Precautions (5.1)]
- Opportunistic infections: herpes zoster [see Warnings and Precautions (5.3)]

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice.

6.1 Clinical Trials Experience in Severe Asthma

Adult and Adolescent Patients Aged 12 Years and Older

A total of 1,327 patients with severe asthma were evaluated in 3 randomized, placebo-controlled, multicenter trials of 24 to 52 weeks' duration (Trial 1, NCT01000506; Trial 2, NCT01691521; and Trial 3, NCT01691508). Of these, 1,192 had a history of 2 or more exacerbations in the year prior to enrollment despite regular use of high-dose ICS plus additional controller(s) (Trials 1 and 2), and 135 patients required daily oral corticosteroids (OCS) in addition to regular use of high-dose ICS plus additional controller(s) to maintain asthma control (Trial 3). All patients had markers of eosinophilic airway inflammation [see Clinical Studies (14.1) of full prescribing information]. Of the patients enrolled, 59% were female, 85% were White, and ages ranged from 12 to 82 years. Mepolizumab was administered subcutaneously or intravenously once every 4 weeks; 263 patients received NUCALA (mepolizumab 100 mg subcutaneous) for at least 24 weeks. Serious adverse events that occurred in more than 1 patient and in a greater percentage of patients receiving NUCALA 100 mg (n = 263) than placebo (n = 257) included 1 event, herpes zoster (2 patients vs. 0 patients, respectively). Approximately 2% of patients receiving NUCALA 100 mg withdrew from clinical trials due to adverse events compared with 3% of patients receiving placebo. The incidence of adverse reactions in the first 24 weeks of treatment in the 2 confirmatory efficacy and safety trials (Trials 2 and 3) with NUCALA 100 mg is shown in Table 1.

Table 1. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with Severe Asthma (Trials 2 and 3)

Adverse Reaction	NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 263) %	Placebo (n = 257) %
Headache	19	18
Injection site reaction	8	3
Back pain	5	4
Fatigue	5	4
Influenza	3	2
Urinary tract infection	3	2
Abdominal pain upper	3	2
Pruritus	3	2
Eczema	3	<1
Muscle spasms	3	<1

52-Week Trial: Adverse reactions from Trial 1 with 52 weeks of treatment with mepolizumab 75 mg intravenous (IV) (n = 153) or placebo (n = 155) and with ≥3% incidence and more common than placebo and not shown in Table 1 were: abdominal pain, allergic rhinitis, asthenia, bronchitis, cystitis, dizziness, dyspnea, ear infection, gastroenteritis, lower respiratory tract infection, musculoskeletal pain, nasal congestion, nasopharyngitis, nausea, pharyngitis, pyrexia, rash, toothache, viral infection, viral respiratory tract infection, and vomiting. In addition, 3 cases of herpes zoster occurred in patients receiving mepolizumab 75 mg IV compared with 2 patients in the placebo group.

Systemic Reactions, including Hypersensitivity Reactions: In Trials 1, 2, and 3 described above, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 3% in the group receiving NUCALA 100 mg and 5% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 1% of patients in the group receiving NUCALA 100 mg and 2% of patients in the placebo group. The most commonly reported manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving NUCALA 100 mg included rash, pruritus, headache, and myalgia. Systemic non-allergic reactions were reported by 2% of patients in the group receiving NUCALA 100 mg and 3% of patients in the placebo group. The most commonly reported manifestations of systemic non-allergic reactions reported in the group receiving NUCALA 100 mg included rash, flushing, and myalgia. A majority of the systemic reactions in patients receiving NUCALA 100 mg (5/7) were experienced on the day of dosing.

Injection Site Reactions: Injection site reactions (e.g., pain, erythema, swelling, itching, burning sensation) occurred at a rate of 8% in patients receiving NUCALA 100 mg compared with 3% in patients receiving placebo. **Long-term Safety:** Nine hundred ninety-eight patients received NUCALA 100 mg in ongoing open-label extension studies, during which additional cases of herpes zoster were reported. The overall adverse event profile has been similar to the asthma trials described above.

Pediatric Patients Aged 6 to 11 Years

The safety data for NUCALA is based upon 1 open-label clinical trial that enrolled 36 patients with severe asthma aged 6 to 11 years. Patients received 40 mg (for those weighing <40 kg) or 100 mg (for those weighing ≥40 kg) of NUCALA administered subcutaneously once every 4 weeks. Patients received NUCALA for 12 weeks (initial short phase). After a treatment interruption of 8 weeks, 30 patients received NUCALA for a further 52 weeks (long phase). The adverse reaction profile for patients aged 6 to 11 years was similar to that observed in patients aged 12 years and older.

6.2 Clinical Trials Experience in Chronic Rhinosinusitis with Nasal Polyps

A total of 407 patients with CRSwNP were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received NUCALA 100 mg or placebo subcutaneously once every 4 weeks. Patients had recurrent CRSwNP with a history of prior surgery and were on nasal corticosteroids for at least 8 weeks prior to screening [see Clinical Studies (14.2) of full prescribing information]. Of the patients enrolled, 35% were female, 93% were White, and ages ranged from 18 to 82 years. Approximately 2% of patients receiving NUCALA 100 mg withdrew from study treatment due to adverse events compared with 2% of patients receiving placebo. Table 2 summarizes adverse reactions that occurred in ≥3% of NUCALA-treated patients and more frequently than in patients treated with placebo in the CRSwNP trial.

Table 2. Adverse Reactions with NUCALA with ≥3% Incidence and More Common than Placebo in Patients with CRSwNP

Adverse Reaction	NUCALA (Mepolizumab 100 mg Subcutaneous) (n = 206) %	Placebo (n = 201) %
Oropharyngeal pain	8	5
Arthralgia	6	2
Abdominal Pain Upper	3	2
Diarrhea	3	2
Pyrexia	3	2
Nasal dryness	3	<1
Rash	3	<1

CRSwNP = Chronic Rhinosinusitis with Nasal Polyps.

Systemic Reactions, including Hypersensitivity Reactions

In the 52-week trial, the percentage of patients who experienced systemic (allergic [type I hypersensitivity] and other) reactions was <1% in the group receiving NUCALA 100 mg and <1% in the placebo group. Systemic allergic (type I hypersensitivity) reactions were reported by <1% of patients in the group receiving NUCALA 100 mg and no patients in the placebo group. The manifestations of systemic allergic (type I hypersensitivity) reactions included urticaria, erythema, and rash and 1 of the 3 reactions occurred on the day of dosing. Other systemic reactions were reported by no patients in the group receiving NUCALA 100 mg and <1% of patients in the placebo group.

Injection Site Reactions

Injection site reactions (e.g., erythema, pruritus) occurred at a rate of 2% in patients receiving NUCALA 100 mg compared with <1% in patients receiving placebo.

6.3 Clinical Trials Experience in Eosinophilic Granulomatosis with Polyangiitis

A total of 136 patients with EGPA were evaluated in 1 randomized, placebo-controlled, multicenter, 52-week treatment trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients enrolled had a diagnosis of EGPA for at least 6 months prior to enrollment with a history of relapsing or refractory disease and were on a stable dosage of oral prednisolone or prednisone of greater than or equal to 7.5 mg/day (but not greater than 50 mg/day) for at least 4 weeks prior to enrollment [see Clinical Studies (14.3) of full prescribing information]. Of the patients enrolled, 59% were female, 92% were White, and ages ranged from 20 to 71 years. No additional adverse reactions were identified to those reported in the severe asthma trials.

Systemic Reactions, including Hypersensitivity Reactions

In the 52-week trial, the percentage of patients who experienced systemic (allergic and non-allergic) reactions was 6% in the group receiving 300 mg of NUCALA and 1% in the placebo group. Systemic allergic/hypersensitivity reactions were reported by 4% of patients in the group receiving 300 mg of NUCALA and 1% of patients in the placebo group. The manifestations of systemic allergic/hypersensitivity reactions reported in the group receiving 300 mg of NUCALA included rash, pruritus, flushing, fatigue, hypertension, warm sensation in trunk and neck, cold extremities, dyspnea, and stridor. Systemic non-allergic reactions were reported by 1 (1%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of systemic non-allergic reactions reported in the group receiving 300 mg of NUCALA was angioedema. Half of the systemic reactions in patients receiving 300 mg of NUCALA (2/4) were experienced on the day of dosing.

Injection Site Reactions

Injection site reactions (e.g., pain, erythema, swelling) occurred at a rate of 15% in patients receiving 300 mg of NUCALA compared with 13% in patients receiving placebo.

6.4 Clinical Trials Experience in Hypereosinophilic Syndrome

A total of 108 adult and adolescent patients aged 12 years and older with HES were evaluated in a randomized, placebo-controlled, multicenter, 32-week treatment trial. Patients with non-hematologic secondary HES or FIP1L1-PDGFRα kinase-positive HES were excluded from the trial. Patients received 300 mg of NUCALA or placebo subcutaneously once every 4 weeks. Patients must have been on a stable dose of background HES therapy for the 4 weeks prior to randomization [see Clinical Studies (14.4) of full prescribing information]. Of the patients enrolled, 53% were female, 93% were White, and ages ranged from 12 to 82 years. No additional adverse reactions were identified to those reported in the severe asthma trials.

Systemic Reactions, including Hypersensitivity Reactions

In the trial, no systemic allergic (type I hypersensitivity) reactions were reported. Other systemic reactions were reported by 1 (2%) patient in the group receiving 300 mg of NUCALA and no patients in the placebo group. The reported manifestation of other systemic reaction was multifocal skin reaction experienced on the day of dosing.

(continued on next page)

6 ADVERSE REACTIONS (cont'd)

Injection Site Reactions

Injection site reactions (e.g., burning, itching) occurred at a rate of 7% in patients receiving 300 mg of NUCALA compared with 4% in patients receiving placebo.

6.5 Immunogenicity

In adult and adolescent patients with severe asthma receiving NUCALA 100 mg, 15/260 (6%) had detectable anti-mepolizumab antibodies. Neutralizing antibodies were detected in 1 patient with asthma receiving NUCALA 100 mg. Anti-mepolizumab antibodies slightly increased (approximately 20%) the clearance of mepolizumab. There was no evidence of a correlation between anti-mepolizumab antibody titers and change in eosinophil level. The clinical relevance of the presence of anti-mepolizumab antibodies is not known. In the clinical trial of children aged 6 to 11 years with severe asthma receiving NUCALA 40 or 100 mg, 2/35 (6%) had detectable anti-mepolizumab antibodies during the initial short phase of the trial. No children had detectable anti-mepolizumab antibodies during the long phase of the trial.

In patients with CRSwNP receiving NUCALA 100 mg, 6/196 (3%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with CRSwNP.

In patients with EGPA receiving 300 mg of NUCALA, 1/68 (<2%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with EGPA.

In adult and adolescent patients with HES receiving 300 mg of NUCALA, 1/53 (2%) had detectable anti-mepolizumab antibodies. No neutralizing antibodies were detected in any patients with HES.

The reported frequency of anti-mepolizumab antibodies may underestimate the actual frequency due to lower assay sensitivity in the presence of high drug concentration. The data reflect the percentage of patients whose test results were positive for antibodies to mepolizumab in specific assays. The observed incidence of antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.

6.6 Postmarketing Experience

In addition to adverse reactions reported from clinical trials, the following adverse reactions have been identified during postapproval use of NUCALA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These events have been chosen for inclusion due to either their seriousness, frequency of reporting, or causal connection to NUCALA or a combination of these factors.

Immune System Disorders

Hypersensitivity reactions, including anaphylaxis.

7 DRUG INTERACTIONS

Formal drug interaction trials have not been performed with NUCALA.

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy

Pregnancy Exposure Registry

There is a pregnancy exposure registry that monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy. Healthcare providers can enroll patients or encourage patients to enroll themselves by calling 1-877-311-8972 or visiting www.mothersbaby.org/asthma.

Risk Summary

The data on pregnancy exposure are insufficient to inform on drug-associated risk. Monoclonal antibodies, such as mepolizumab, are transported across the placenta in a linear fashion as pregnancy progresses; therefore, potential effects on a fetus are likely to be greater during the second and third trimester of pregnancy. In a prenatal and postnatal development study conducted in cynomolgus monkeys, there was no evidence of fetal harm with IV administration of mepolizumab throughout pregnancy at doses that produced exposures up to approximately 9 times the exposure at the maximum recommended human dose (MRHD) of 300 mg subcutaneous (see Data).

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Clinical Considerations

Disease-Associated Maternal and/or Embryofetal Risk: In women with poorly or moderately controlled asthma, evidence demonstrates that there is an increased risk of preeclampsia in the mother and prematurity, low birth weight, and small for gestational age in the neonate. The level of asthma control should be closely monitored in pregnant women and treatment adjusted as necessary to maintain optimal control.

Data

Animal Data: In a prenatal and postnatal development study, pregnant cynomolgus monkeys received mepolizumab from gestation Days 20 to 140 at doses that produced exposures up to approximately 9 times that achieved with the MRHD (on an AUC basis with maternal IV doses up to 100 mg/kg once every 4 weeks). Mepolizumab did not elicit adverse effects on fetal or neonatal growth (including immune function) up to 9 months after birth. Examinations for internal or skeletal malformations were not performed. Mepolizumab crossed the placenta in cynomolgus monkeys. Concentrations of mepolizumab were approximately 2.4 times higher in infants than in mothers up to Day 178 postpartum. Levels of mepolizumab in milk were ≤0.5% of maternal serum concentration.

In a fertility, early embryonic, and embryofetal development study, pregnant CD-1 mice received an analogous antibody, which inhibits the activity of murine interleukin-5 (IL-5), at an IV dose of 50 mg/kg once per week throughout gestation. The analogous antibody was not teratogenic in mice. Embryofetal development of IL-5-deficient mice has been reported to be generally unaffected relative to wild-type mice.

8.2 Lactation

Risk Summary

There is no information regarding the presence of mepolizumab in human milk, the effects on the breastfed infant, or the effects on milk production. However, mepolizumab is a humanized monoclonal antibody (IgG1 kappa), and immunoglobulin G (IgG) is present in human milk in small amounts. Mepolizumab was present in the milk of cynomolgus monkeys postpartum following dosing during pregnancy [see Use in Specific Populations (8.1)]. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for NUCALA and any potential adverse effects on the breastfed infant from mepolizumab or from the underlying maternal condition.

8.4 Pediatric Use

Severe Asthma

The safety and efficacy of NUCALA for severe asthma, and with an eosinophilic phenotype, have been established in pediatric patients aged 6 years and older.

Use of NUCALA in adolescents aged 12 to 17 years is supported by evidence from adequate and well-controlled trials in adults and adolescents. A total of 28 adolescents aged 12 to 17 years with severe asthma were enrolled in the Phase 3 asthma trials. Of these, 25 were enrolled in the 32-week exacerbation trial (Trial 2, NCT01691521) and had a mean age of 14.8 years. Patients had a history of 2 or more exacerbations in the previous year despite regular use of medium- or high-dose ICS plus additional controller(s) with or without OCS and had blood eosinophils of ≥150 cells/mL at screening or ≥300 cells/mL within 12 months prior to enrollment. [See Clinical Studies (14.1) of full prescribing information.] Patients had a reduction in the rate of exacerbations that trended in favor of NUCALA. Of the 19 adolescents who received NUCALA, 9 received 100 mg and the mean apparent clearance in these patients was 35% less than that of adults. The safety profile observed in adolescents was generally similar to that of the overall population in the Phase 3 studies [see Adverse Reactions (6.1)]. Use of NUCALA in pediatric patients aged 6 to 11 years with severe asthma, and with an eosinophilic phenotype, is supported by evidence from adequate and well-controlled trials in adults and adolescents with additional pharmacokinetic, pharmacodynamic, and safety data in children aged 6 to 11 years. A single, open-label clinical trial (NCT02377427) was conducted in 36 children aged 6 to 11 years (mean age: 8.6 years, 31% female) with severe asthma. Enrollment criteria were the same as for adolescents in the 32-week exacerbation trial (Trial 2). Based upon the pharmacokinetic data from this trial, a dose of 40 mg subcutaneous every 4 weeks was determined to have similar exposure to adults and adolescents administered a dose of 100 mg SC [see Clinical Pharmacology (12.3) of full prescribing information].

The effectiveness of NUCALA in pediatric patients aged 6 to 11 years is extrapolated from efficacy in adults and adolescents with support from pharmacokinetic analyses showing similar drug exposure levels for 40 mg administered subcutaneously every 4 weeks in children aged 6 to 11 years compared with adults and adolescents [see Clinical Pharmacology (12.3) of full prescribing information]. The safety profile and pharmacodynamic response observed in this trial for children aged 6 to 11 years were similar to that seen in adults and adolescents [see Adverse Reactions (6.1), Clinical Pharmacology (12.2) of full prescribing information]. The safety and effectiveness in pediatric patients aged younger than 6 years with severe asthma have not been established.

Chronic Rhinosinusitis with Nasal Polyps

The safety and effectiveness in patients aged younger than 18 years with CRSwNP have not been established.

Eosinophilic Granulomatosis with Polyangiitis

The safety and effectiveness in patients aged younger than 18 years with EGPA have not been established.

Hyper eosinophilic Syndrome

The safety and effectiveness of NUCALA for HES have been established in adolescent patients aged 12 years and older. The safety and effectiveness in pediatric patients aged younger than 12 years with HES have not been established.

Use of NUCALA for this indication is supported by evidence from an adequate and well-controlled study (NCT02836496) in adults and adolescents and an open-label extension study (NCT03306043). One adolescent received NUCALA during the controlled study and this patient and an additional 3 adolescents received NUCALA during the open-label extension study [see Clinical Studies (14.4) of full prescribing information]. The 1 adolescent treated with NUCALA in the 32-week trial did not have a HES flare or an adverse event reported. All adolescents received 300 mg of NUCALA for 20 weeks in the open-label extension.

8.5 Geriatric Use

Clinical trials of NUCALA did not include sufficient numbers of patients aged 65 years and older that received NUCALA (n = 79) to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy. Based on available data, no adjustment of the dosage of NUCALA in geriatric patients is necessary, but greater sensitivity in some older individuals cannot be ruled out.

10 OVERDOSAGE

There is no specific treatment for an overdose with mepolizumab. If overdose occurs, the patient should be treated supportively with appropriate monitoring as necessary.

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Hypersensitivity Reactions

Inform patients that hypersensitivity reactions (e.g., anaphylaxis, angioedema, bronchospasm, hypotension, urticaria, rash) have occurred after administration of NUCALA. Instruct patients to contact their physicians if such reactions occur.

Not for Acute Symptoms or Deteriorating Disease

Inform patients that NUCALA does not treat acute asthma symptoms or acute exacerbations. Inform patients to seek medical advice if their asthma remains uncontrolled or worsens after initiation of treatment with NUCALA.

Opportunistic Infections: Herpes Zoster

Inform patients that herpes zoster infections have occurred in patients receiving NUCALA and where medically appropriate, inform patients that vaccination should be considered.

Reduction of Corticosteroid Dosage

Inform patients to not discontinue systemic or inhaled corticosteroids except under the direct supervision of a physician. Inform patients that reduction in corticosteroid dose may be associated with systemic withdrawal symptoms and/or unmask conditions previously suppressed by systemic corticosteroid therapy.

Pregnancy Exposure Registry

Inform women there is a pregnancy exposure registry that monitors pregnancy outcomes in women with asthma exposed to NUCALA during pregnancy and that they can enroll in the Pregnancy Exposure Registry by calling 1-877-311-8972 or by visiting www.mothersbaby.org/asthma [see Use in Specific Populations (8.1)].

Trademarks are owned by or licensed to the GSK group of companies.

Manufactured by
GlaxoSmithKline LLC
Philadelphia, PA 19112
U.S. License Number 1727

Distributed by



GlaxoSmithKline
Research Triangle Park, NC 27709

©2021 GSK group of companies or its licensor.

Revised: 7/2021

©2021 GSK or licensor.
MPLJRNA210003 December 2021
Produced in USA.

NCL:7BRS

advocates hope will become more common in pulmonary care. They're working to convince colleagues that PC is neither another word for hospice nor a sign that anyone is giving up on a patient.

Underutilized but beneficial

"Palliative care is underutilized in patients with chronic pulmonary disease, and it's a missed opportunity to potentially alleviate symptoms and improve quality of life," said Hilary DuBrock, MD, an internist and critical care pulmonologist with the Mayo Clinic in Rochester, Minn. "Chest physicians should know that it's important to recognize your limitations in addressing all aspects of a chronic disease, and it's OK to ask for help from a specialty multidisciplinary team of palliative care providers."

Statistics back up Dr. DuBrock's perspective about how PC isn't common in pulmonary care. A 2017 study examined 181,689 U.S. adult patients who had COPD, received oxygen at home, and were hospitalized for exacerbations from 2006 to 2012 (CHEST. 2017 Jan 1;151[1]:41-6). Just 1.7% received PC, although the number grew over the study period.

Another study published in 2017 examined 3,166 patients over the same period with end-stage idiopathic pulmonary fibrosis (IPF) who were on ventilators (Am J Hosp Palliat Care. 2017 Jun 12. doi: 10.1177/10499091177139900). The use of PC is group rose from 2.3% in 2006 to 21.6% in 2012.

A more recent meta-analysis (Palliat Med. 2020 Jun 2. doi: 10.1177/2F0269216320929556) examined 19 studies and found that patients with lung cancer were much more likely to receive PC than were those with COPD (odds ratio, 9.59; $P < .001$, for hospital-based PC and OR, 8.79; $P < .001$, for home-based PC).

Patients with lung cancer vs. COPD were also less likely to receive invasive ventilation (OR, .26; $P < .001$), noninvasive ventilation (OR, .63; $P = .009$) or CPR (OR, .29; $P < .001$) or die at a nursing home/long-term care facility (OR, .32; $P < .001$).

Other studies support PC in COPD: Research in Europe has linked PC in COPD to fewer in-hospital deaths and lower end-of-life expenses. A Canadian study also linked PC to fewer in-hospital deaths in COPD (Ann Am Thorac Soc. 2021. doi: 10.1513/AnnalsATS.202007-859OC).

Dr. DuBrock said she believes there are a couple reasons why PC isn't more widely accepted in pulmonology. "There has been little evidence in chronic pulmonary disease regarding the role of PC, and there is a lack of standardized guidelines to help clinicians determine appropriate timing and patient selection for referral," she said. "There is also a reluctance to refer patients to palliative care since some may think that referral implies that they are giving up on their patients."

In fact, she said, "if appropriately explained and discussed with patients, PC does not necessarily need to imply to patients that you are giving up on them, but rather that you care enough about them to try to find novel ways to improve their quality of life and relieve their symptoms. Additionally, palliative care can be provided alongside ongoing medical care and treatment of their chronic lung disease."

More than standard care

Another obstacle comes from pulmonologists who claim PC isn't necessary because they're handling patient care themselves, said University of Alabama at Birmingham critical care pulmonologist Anand S. Iyer, MD. "They'll say: 'I do palliative care; I palliate their breathing. I treat breathlessness and cough; that's what I do.'"

But these symptoms brush only the surface of patient needs, he said. "I don't think that the average pulmonologist goes beyond that to comprehensive symptom assessment and management of a whole host of symptoms beyond those limited to the lungs – depression, anxiety, fatigue, malnutrition."

On that latter front, he said, pulmonologists "are really good at having end-of-life conversations at the end of life. We do that every day in the ICU." Advocates for PC, he said, "want to push that to the clinic a year or 2 earlier."

Timing and use of PC

When should pulmonologists call in a PC team? Specialists recommend early consultations, even right after a pulmonary disease is diagnosed. "When a pulmonologist diagnoses a condition as a serious illness – especially chronic pulmonary disease – a consultation with a palliative care physician or advanced practice registered nurse" can help assess the need for care and the best time to introduce palliative care to the patient and family "to provide relief

PALLIATIVE CARE continued on following page

PULMONARY PERSPECTIVES® //

20

CHEST PHYSICIAN IS ONLINE

CHEST Physician is available at chestphysician.org.



Angel Coz, MD, FCCP, is Editor in Chief of CHEST Physician.

CHEST Physician®

THE NEWSPAPER OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS

AMERICAN COLLEGE OF CHEST PHYSICIANS (CHEST)

EDITOR IN CHIEF

Angel Coz, MD, FCCP

PRESIDENT

David Schulman, MD, MPH, FCCP

EXECUTIVE VICE PRESIDENT & CEO

Robert Musacchio, PhD

PUBLISHER, CHEST

Nicki Augustyn, CAE

MANAGER, EDITORIAL RESOURCES

Pamela L. Goorsky

MANAGING EDITOR, NEWS CHANNELS

Danielle Leber

SECTION EDITORS

Aaron B. Holley, MD, FCCP

Pulmonary Perspectives®

Daniel R. Ouellette, MD, FCCP

Critical Care Commentary

Michelle Cao, DO, FCCP

Sleep Strategies

EDITORIAL ADVISORY BOARD

Humayun Anjum, MD, FCCP

A. Christine Argento, MD, FCCP

Abbie Begnaud, MD, FCCP

David L. Bowton, MD, FCCP

Mary Cataletto, MD, FCCP

Carolyn D'Ambrosio, MD, FCCP

Mary Jo S. Farmer, MD, PhD, FCCP

Sachin Gupta, MD, FCCP

Loren Harris, MD, FCCP

Jonathan Ludmir, MD

Diego Maselli, MD, FCCP

Mangala Narasimhan, DO, FCCP

Brandon M. Seay, MD

Shyam Subramanian, MD, FCCP

Sai Venkateshlah, MD, FCCP

E-mail: chestphysiciannews@chestnet.org

©Copyright 2022, by the American College of Chest Physicians



FRONTLINE MEDICAL COMMUNICATIONS SOCIETY PARTNERS

EXECUTIVE EDITOR Kathy Scarbeck, MA

EDITOR Mark S. Lesney, PhD

CREATIVE DIRECTOR Louise A. Koenig

DIRECTOR, PRODUCTION/MANUFACTURING

Rebecca Slebodnik

DIRECTOR, BUSINESS DEVELOPMENT

Monique Michowski,
973-206-8015, cell 732-278-4549,
mmichowski@mdedge.com

RECRUITMENT SALES REPRESENTATIVE

Linda Wilson 973-290-8243,
lwilson@mdedge.com

SENIOR DIRECTOR OF RECRUITMENT SALES

Tim LaPella, 484-921-5001,
tlapella@mdedge.com

CHEST PHYSICIAN, the newspaper of the American College of Chest Physicians, provides cutting-edge reports from clinical meetings, FDA coverage, clinical trial results, expert commentary, and reporting on the business and politics of chest medicine. Each issue also provides material exclusive to CHEST members. Content for CHEST PHYSICIAN is provided by Frontline Medical Communications Inc. Content for News From Chest is provided by the American College of Chest Physicians.

The statements and opinions expressed in CHEST PHYSICIAN do not necessarily reflect those of the American College of Chest Physicians, or of its officers, regents, members, and employees, or those of the Publisher. The American College of Chest Physicians, its officers, regents, members, and employees, and Frontline Medical Communications Inc. do not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to products, drugs, or services mentioned herein.

POSTMASTER: Send change of address (with old mailing label) to CHEST PHYSICIAN, Subscription Services, 10255 W Higgins Road, Suite 280, Rosemont, IL 60018-9914.

RECIPIENT: To change your address, contact Subscription Services at 1-800-430-5450. For paid subscriptions, single issue purchases, and missing issue claims, call Customer Service at 1-833-836-2705 or e-mail custsvc.chph@fulcoinc.com

CHEST PHYSICIAN (ISSN 1558-6200) is published monthly for the American College of Chest Physicians by Frontline Medical Communications Inc., 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Subscription price is \$244.00 per year. Phone 973-206-3434, fax 973-206-9378.

EDITORIAL OFFICES 2275 Research Blvd, Suite 400, Rockville, MD 20850, 973-206-3434, fax 240-221-2548

ADVERTISING OFFICES 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609 973-206-3434, fax 973-206-9378

FRONTLINE MEDICAL COMMUNICATIONS

Corporate

VP, SALES Mike Guire

VP, MEMBER MARKETING & DIGITAL

PRODUCTION Amy Pfeiffer

PRESIDENT, CUSTOM SOLUTIONS JoAnn Wahl

CIRCULATION DIRECTOR Jared Sonners

DIRECTOR, CUSTOM PROGRAMS Patrick Finnegan

VICE PRESIDENT, PROPRIETARY CONFERENCES, MEDSCAPE LIVE David J. Small, MBA

to affect so many organ systems,” he said. “This paper sheds some light and may help explain why long COVID can occur even in people who had mild or asymptomatic acute disease.”

The NIH researchers sampled and analyzed tissues from autopsies on 44 patients who died after contracting the coronavirus during the first year of the pandemic. They found persistent virus particles in multiple parts of the body, including the heart and brain, for as long as 230 days after symptoms began. This could represent infection with defective virus particles, they said, which has also been seen in persistent infections among measles patients.

“We don’t yet know what burden of chronic illness will result in years to come,” Raina Mac-

Intyre, PhD, a professor of global biosecurity at the University of New South Wales, Sydney, told Bloomberg News.

“While the highest burden of SARS-CoV-2 is in the airways and lung, the virus can disseminate early during infection and infect cells throughout the entire body, including widely throughout the brain.”

“Will we see young-onset cardiac failure in survivors or early-onset dementia?” she asked. “These are unanswered questions which call for a precautionary public health approach to mitiga-

tion of the spread of this virus.”

Unlike other COVID-19 autopsy research, the NIH team had a more comprehensive postmortem tissue collection process, which typically occurred within a day of the patient’s death, Bloomberg News reported. The researchers also used a variety of ways to preserve tissue to figure out viral levels. They were able to grow the virus collected from several tissues, including the heart, lungs, small intestine, and adrenal glands.

“Our results collectively show that, while the highest burden of SARS-CoV-2 is in the airways and lung, the virus can disseminate early during infection and infect cells throughout the entire body, including widely throughout the brain,” the study authors wrote. ■

PALLIATIVE CARE *continued from previous page*

and enhance quality of life,” West Virginia University’s Dr. Narsavage said. “Initial diagnosis is not too early to think about the trajectory.

Dr. Iyer agreed that early PC consultation is key. “We’re talking about comprehensive support for the physical, emotional, and spiritual needs of patients and their families. It can grow as needs of patients become more severe.”

For her part, Dr. DuBrock urged colleagues to focus on patient experiences. “The exact timing of when to refer patients with pulmonary disease is not well established,” she said. “Thus, it’s important to take cues from our patients. If they are experiencing significant symptom burden or impaired quality of life or having difficulty coping with their lung disease, then it may be helpful to call in palliative care to address these issues alongside education and discussion with the patient about the role of palliative care to address their unmet needs.”

As an example, Dr. DuBrock spoke of one of her own patients who has pulmonary hypertension (PH), connective tissue disease, and interstitial lung disease. “Her hypertension was relatively well controlled, but she was still quite symptomatic as well as depressed and having difficulty sleeping. I struggled with wanting to help her feel better but I also recognized that more PH therapy wasn’t necessarily the answer,” Dr. DuBrock said. “After some discussions, I referred her to palliative care, and they were extremely helpful with addressing her symptoms with a combination of pharmacologic and nonpharmacologic therapy and also addressing some of her underlying concerns and fears regarding her prognosis and issues related to advance-care planning. Social work was also helpful with addressing some of her financial concerns. I continue to see her on regular basis and treat her PH, but

her overall quality of life, sleep, and mood have improved substantially.”

First steps

According to specialists, the first step in the PC process with patients is to make sure they understand their conditions, their prognoses, and the role of palliative care itself.

Kathleen Oare Lindell, PhD, RN, associate professor of nursing at Medical University of South Carolina, Charleston, who specializes in PC in pulmonary disease, remembers taking the histories of patients

“When a pulmonologist diagnoses a condition as a serious illness – especially chronic pulmonary disease – a consultation with a palliative care physician or advanced practice registered nurse” can help assess the need for care.

with grim prognoses and “their look on their face was like, ‘I just have a common cold.’” In other cases, she said, patients may fear they’ll die immediately when they have 3-5 years to live.

Dr. Lindell, who has worked at a center for patients with interstitial lung disease, emphasized the importance of speaking in layperson terms that patients understand, such as referring to idiopathic pulmonary fibrosis as “unknown lung scarring.” She also said it’s crucial to be up front about their prognoses.

As for patient understanding of PC, she said, “people think it’s hospice that they’re giving. Palliative care is neither. Instead, it helps to address symptom management: I always tell patients, ‘You’ll be scared; you’ll have a cough. There are medicines and nonpharmacological therapies [that can help], and that’s what

palliative care does.’”

Keith Swetz, MD, an internist and palliative care specialist at the University of Alabama at Birmingham, agreed that a concise discussion of prognosis is vital. “What do they know about their illness, and what do they understand about what will happen when things get worse?” he said.

“With pulmonary disease, they may be looking at months to years punctuated with a lot of ICU admissions, trips to the hospital, symptom burden, and decline in function. Some will want aggressive treatment and say they’re fine being in the hospital, while others will say being comfortable at home is more important.”

Dr. Swetz’s patients commonly have COPD, interstitial lung disease, pulmonary fibrosis, or PH, and some may have concurrent heart failure. While their prognoses may be poor, he said, discussion about their wishes probably aren’t happening outside of the PC setting.

Or if they are happening, he said, they’re lower quality, boiling down complicated care questions to “Do you want us to do everything, yes or no?”

“A lot of it has to do with time,” he said. “Clinicians are busy, they might have a full ICU or pulmonary clinic with 15 minutes to see patients. Sitting down and talking about these things isn’t something that’s prioritized or fits into the work stream very well, and often it hasn’t been reimbursed.”

There typically aren’t insurance hassles regarding referrals for PC, Dr. Iyer said, although finding available specialists may be challenging. A 2019 study (Health Aff. 2019 Jun. doi: 10.1377/hlthaff.2019.00018) projected a wave of retirements of older PC physicians over the next few years, and the ratio of patients to PC specialists may not return to 2019 levels for decades. Rural areas are

especially shorthanded. But telehealth may improve access, Dr. Iyer said.

What’s next? Specialists are trying to pin down guidelines for when PC consultation is appropriate in pulmonary disease.

Triggers to PC

Dr. Iyer, Dr. Lindell, and others authored a 2021 report in the journal CHEST that offers guidance about triggers for PC consultation (doi: 10.1016/j.chest.2021.10.032). The authors cited four “levers” or triggers that are important: worsening lung function, severe symptoms or high burden of care needs, poor prognosis, and frequent severe exacerbations. “The overall point here is that integrating palliative care into COPD practice isn’t an on-off switch; rather, it should be based upon multiple factors and can evolve over time,” they wrote.

They noted that, “patients with COPD accept palliative care as early as moderate COPD (FEV₁ < 80%), so patients may be ready sooner than clinicians think.” They added that, “if prognosis is such a concern that a clinician is considering referral for lung transplant evaluation, then concurrent referral to specialist palliative care should be routine practice.

Finally, frequent severe exacerbations, i.e., those that require hospitalization or an emergency room visit, carry a high risk for posthospitalization mortality and are ideal inflection points in the illness trajectory of COPD.”

In the big picture, the authors contend, “palliative care should be integrated early and concurrently with COPD-directed therapies, and its intensity should increase over time as symptoms, needs, and exacerbations worsen approaching EOL [end of life].”

None of the interviewees or other authors reported having any relevant conflicts for this story. ■

Frail COPD patients at high risk of disability and death

BY PAM HARRISON

Patients with chronic obstructive pulmonary disease (COPD) who are both frail and who have poor lung function or dyspnea are at especially high risk of disability within 3-5 years as well as all-cause mortality years later, a prospective cohort study of community-dwelling adults has shown.

“Frailty, a widely recognized geriatric syndrome characterized by multidimensional functional decline in bio-psycho-social factors, is associated with functional disability and mortality,” senior author Tze Pin Ng, MD, National University of Singapore, and colleagues explain.

“Our results ... suggest that beyond traditional prognostic markers such as FEV₁% (forced expiratory volume in 1 second) and dyspnea, the physical frailty phenotype provides additional useful prognostic information on future risks of disability and mortality,” the authors suggest.

The study was published online in CHEST (2021. doi: 10.1016/j.chest.2021.12.633).

SLAS-1 and SLAS-2

Data from the Singapore Longitudinal Ageing Study (SLAS-1) and SLAS-2 were collected and analyzed. SLAS-1 recruited 2,804 participants 55 years of age and older from September 2003 through December 2004, while SLAS-2 recruited 3,270 participants of the same age between March 2009 and June 2013. “Follow-up visits and assessments were conducted approximately 3-5 years apart,” the investigators noted.

Mortality was determined at a mean of 9.5 years of follow-up for SLAS-1 participants and a mean of 6.5 years’ follow-up for SLAS-2 participants. A total of 4,627 participants were eventually included in the analysis, of whom 1,162 patients had COPD and 3,465 patients did not. COPD was classified as mild if FEV₁% was greater than or equal to 80%; moderate if FEV₁% was greater than or equal to 50% to less than 80%, and severe if FEV₁% was less than 50%.


Frailty in turn was based on five clinical criteria, including weakness, slowness, low physical activity, exhaustion, and shrinking. Participants were classified as frail if they met three or more of these criteria and prefrail if they met one or two criteria.

Adverse health outcomes were judged on the basis of instrumental or basic activities of daily living (IADL/ADL), while disability was judged by self-reported difficulties in or requiring assistance with at least one IADL or ADL.

Frail or prefrail

Almost half of the participants were frail or prefrail, as the authors reported, while 25% had COPD. Among the participants with COPD, 30% had moderate to severe COPD, 6.4% had dyspnea, and almost half had prefrailty, while approximately 7% were classified as frail.

This percentage was 86% higher than it was for participants without COPD, among whom just 3.2% were assessed as frail, at an odds ratio of 1.86 (95% CI, 1.35-2.56). Further adjustments for



possible confounders reduced the gap between frail COPD and frail non-COPD participants, but frailty remained significantly associated with COPD, at an OR of 1.61 (95% CI, 1.15-2.26), the investigators note.

Furthermore, compared to those without COPD, a diagnosis of COPD without and with dyspnea was associated with a 1.5- and 4.2-fold increase in prevalent frailty (95% CI, 1.04-2.08; 1.84-9.19), respectively, although not with prefrailty. Again, with adjustment for multiple confounders, FEV₁%, dyspnea, and both prefrailty and frailty were associated with an approximately twofold higher prevalence of IADL/ADL disability, while the prevalence of IADL/ADL disability for participants with COPD was approximately fourfold higher in those with co-occurring FEV₁% less than 80% with either prefrailty, frailty, or dyspnea.

Furthermore, the presence of prefrailty or frailty in combination with a lower FEV₁% or dyspnea was associated with a 3.7- to 3.8-fold increased risk of having an IADL or ADL disability.

Frailty and mortality

Some 1,116 participants with COPD were followed for a mean of 2,981 days for mortality outcomes. Both FEV₁% less than 50% and the presence of prefrailty and frailty almost doubled the risk of mortality, at an adjusted hazard ratio of 1.8 (95% CI, 1.24-2.68) compared to patients with an FEV₁% greater than or equal to 80%. In combination with either FEV₁% less than 80% or prefrailty/frailty, dyspnea almost more than doubled the risk of mortality, at an HR of 2.4 for both combinations.

“However, the mortality risk of participants with COPD was highest among those with FEV₁% less than 80% and prefrailty/frailty,” the authors note, more than tripling mortality risk at an adjusted HR of 3.25 (95% CI, 1.97-5.36). Interestingly, FEV₁% less than 80% and prefrailty/frailty – both alone and in combination – were also associated with a twofold to fourfold increased risk of IADL

or ADL disability in participants without COPD but were less strongly associated with mortality.

Researchers then went on to create a summary risk score containing all relevant variables with values ranging from 0 to 5. The highest risk category of 3-5 was associated with a 7- to 8.5-fold increased risk for IADL and ADL disability and mortality among participants with COPD, and that risk remained high after adjusting for multiple confounders.

Of note, frailty did not significantly predict mortality in women, while dyspnea did not significantly predict mortality in men. “Recognition and assessment of physical frailty in addition to FEV₁% and dyspnea would allow for more accurate identification and targeted treatment of COPD at risk of future adverse outcomes,” the authors suggest.

Frailty scoring system

Asked to comment on the study, Sachin Gupta, MD, FCCP, a pulmonologist and critical care specialist at Alameda Health System in Oakland, Calif., noted that the current study adds to the body of literature that outcomes in patients with COPD depend as much on objectively measured variables as on qualitative measures.

“By applying a frailty scoring system, these researchers were able to categorize frailty and study its impact on patient characteristics and outcomes,” he told this news organization in an email.

The summary risk assessment tool developed and assessed is familiar: It carries parallels to the widely utilized BODE Index, replacing body mass index and 6-minute walk distance with the frailty scale, he added. “Findings from this study support the idea that what meets the eye in face-to-face visits – frailty – can be codified and be part of a tool that is predictive of outcomes,” Dr. Gupta underscored.

The authors had no conflicts of interest to declare. Dr. Gupta disclosed that he is also an employee and shareholder at Genentech. ■

Is early-detection stage shift driving mortality decline?

BY JIM KLING

In non-small cell lung cancer (NSCLC), earlier detection may be an underappreciated factor in recent trends of declining mortality, according to a new analysis of data from the Surveillance, Epidemiology, and End Results (SEER) registries published in JAMA Network Open (2021 Dec 17. doi: 10.1001/jamanetworkopen.2021.37508). Between 2006 and 2016, a stage shift occurred with an increase in stage 1 and 2 diagnoses and a decrease in stage 3 and 4 diagnoses.

While targeted therapy and immunotherapy have rightfully been credited with improved NSCLC survival, the new results underline the importance of screening, according to study author Emanuela Taioli, MD, PhD, director of the Institute for Translational Epidemiology and the associate director for population science at the Tisch Cancer Institute at Mount Sinai, New York.

She noted that the average survival for stage 1 or stage 2 patients was 57 months, but just 7 months when the stage diagnosis was 3 or 4. “So being diagnosed with stage 1 and 2 is a major driver of better survival,” said Dr. Taioli in an interview.

The study included 312,382 individuals diagnosed with NSCLC (53.4% male; median age, 68). Incidence-based, 5-year mortality declined by 3.7% (95% confidence interval, 3.4%-4.1%). Stage 1 or 2 diagnoses increased from 26.5% to 31.2% of diagnoses between 2006 and 2016 (average annual percentage change, 1.5%; 95% CI, 0.5%-2.5%).

“Immunotherapy is a very exciting field. And it is an important contributor for people who have a disease that can be treated with immunotherapy, so that’s why people focus on that. But if you can diagnose the cancer earlier, that’s the best bet.”

Unfortunately, many patients and physicians haven’t received that message. Even though computed tomography lung cancer screening is covered by Medicare for current or former smokers, only about 7% of eligible patients undergo annual screening. Dr. Taioli said that a belief persists that lung cancer is so deadly that early detection isn’t effective.

But advances in therapy and surgery have changed that outlook. “It’s not true anymore. People don’t know, and physicians are not educated to the idea that lung cancer can be diag-

nosed earlier and save lives,” she said.

People who have quit smoking may be relatively easy to convince. “They made a big step, because quitting smoking is incredibly hard.

I think they will be amenable to screening because they are in a phase [of life] in which they want to take care of themselves. The physician should really explain the bene-

fits, and I don’t think they do it very clearly now,” Dr. Taioli said.

The study is limited by its retrospective nature. Dr. Taioli has no relevant financial disclosures. ■



We could send **23,000+** patients to your office to tell you how well the Philips InCourage system works.

Or you could just try it with a few of your patients. We think you—and they—will see the **difference**.

61% Yearly rate of hospitalization decreased

RespirTech patients reported after 12 months of Philips InCourage vest therapy.^{1,2}

Get in touch

Call: 800.793.1261

Fax prescriptions: 800.962.1611

respirtech.com/incourage



RespirTech
A Philips company

Methodology: Phone surveys at regular intervals with bronchiectasis patients using the InCourage system. Data collection began 10/01/2013. As of 05/31/2021, the total cohort was 23,213 patients; 21,049 patients completed the baseline survey; 13,303 patients in 1-month cohort; 9,569 in 6-month cohort; 7,720 in 12-month cohort

Adaptive D-dimer thresholds may rule out PE

BY HEIDI SPLETE

Adapted D-dimer thresholds based on pretest probability were effective for ruling out pulmonary embolism (PE) in subgroups of high-risk individuals without the use of imaging in a review of data.

In a patient suspected to have a PE, “diagnosis is made radiographically, usually with CT pulmonary angiogram, or V/Q scan,” Suman Pal, MD, of the University of New Mexico, Albuquerque, said in an interview.

“Validated clinical decision tools such as Wells’s score or Geneva score may be used to identify patients at low pretest probability of PE who may initially get a D-dimer level check, followed by imaging only if D-dimer level is elevated,” explained Dr. Pal, who was not involved with the new research, which was published in *Annals of Internal Medicine* (2021 Dec 14. doi: 10.7326/M21-2625).

According to the authors of the new paper, while current diagnostic strategies in patients with suspected PE include use of a validated clinical decision rule (CDR) and D-dimer testing to rule out PE without imaging tests, the effectiveness of D-dimer tests in older patients, inpatients, cancer patients, and other high-risk groups has not been well-studied.

Lead author of the paper, Milou A.M. Stals, MD, and colleagues said their goal was to evaluate the safety and efficiency of the Wells rule and revised Geneva score in combination with D-dimer tests, and also the YEARS algorithm for D-dimer thresholds, in their paper.

Dr. Stals of Leiden (the Netherlands) University Medical Center, and coinvestigators conducted an international systemic review and individual patient data meta-analysis that included 16 studies and 20,553 patients, with all studies having been published between Jan. 1, 1995, and Jan. 1, 2021. Their primary outcomes were the safety and efficiency of each of these three strategies.

In the review, the researchers defined safety as the 3-month incidence of venous thromboembolism after PE was ruled out without imaging at baseline. They defined efficiency as the proportion of patients for whom PE was ruled out based on D-dimer

thresholds without imaging.

Overall, efficiency was highest in the subset of patients aged younger than 40 years, ranging from 47% to 68% in this group. Efficiency was lowest in patients aged 80 years and older (6.0%-23%), and in patients with cancer (9.6%-26%).

The efficiency was higher when D-dimer thresholds based on pretest probability were used, compared with when fixed or age-adjusted D-dimer thresholds were used.

The key finding was the significant variability in performance of the diagnostic strategies, the researchers said.

“The predicted failure rate was generally highest for strategies incorporating adapted D-dimer thresholds. However, at the same time, predicted overall efficiency was substantially higher with these strategies versus strategies with a fixed D-dimer threshold as well,” they said. Given that the benefits of each of the three diagnostic strategies depends on their correct application, the researchers recommended that an individual hospitalist choose one strategy for their institution.

“Whether clinicians should rely on the Wells rule, the YEARS algorithm, or the revised Geneva score becomes a matter of local preference and experience,” Dr. Stals and colleagues wrote.

The study findings were limited by several factors including between-study differences in scoring predictors and D-dimer assays. Another limitation was that differential

verification biases for classifying fatal events and PE may have contributed to overestimation of failure rates of the adapted D-dimer thresholds.

Strengths of the study included its large sample size and original data on pretest probability, and that data support the use of any of the three strate-

Overall, efficiency was highest in the subset of patients aged younger than 40 years, ranging from 47% to 68% in this group. Efficiency was lowest in patients aged 80 years and older, and in patients with cancer.

gies for ruling out PE in the identified subgroups without the need for imaging tests, the authors wrote.

“Pending the results of ongoing diagnostic randomized trials, physicians and guideline committees should balance the interlink between safety and efficiency of available diagnostic strategies,” they concluded.

Adapted D-dimer benefits some patients

“Clearly, increasing the D-dimer cutoff will lower the number of patients who require radiographic imaging (improved specificity), but this comes with a risk for missing PE (lower sensitivity). Is this risk worth taking?” Daniel J. Brotman,

MD, of Johns Hopkins University, Baltimore, asked in an editorial accompanying the new study (*Ann Intern Med*. 2021 Dec 14. doi: 10.7326/M21-4295).

Dr. Brotman was not surprised by the study findings.

“Conditions that predispose to thrombosis through activated hemostasis – such as advanced age, cancer, inflammation, prolonged hospitalization, and trauma – drive D-dimer levels higher independent of the presence or absence of radiographically apparent thrombosis,” he said. However, these patients are unlikely to have normal D-dimer levels regardless of the cutoff used.

Adapted D-dimer cutoffs may benefit some patients, including those with contraindications or limited access to imaging, said Dr. Brotman. D-dimer may be used for risk stratification regardless of PE, since patients with marginally elevated D-dimers have better prognoses than those with higher D-dimer elevations, even if a small PE is missed.


Dr. Brotman wrote that increasing D-dimer cutoffs for high-risk patients in the subgroups analyzed may spare some patients radiographic testing, but doing so carries an increased risk for diagnostic failure. Overall, “the important work by Stals and colleagues offers reassurance that modifying D-dimer thresholds according to age or pretest probability is safe enough for widespread practice, even in high-risk groups.”

Focus on single strategy ‘based on local needs’

“Several validated clinical decision tools, along with age or pretest probability-adjusted D-dimer threshold are currently in use as diagnostic strategies for ruling out pulmonary embolism,” Dr. Pal said in an interview.

The current study is important because of limited data on the performance of these strategies in specific subgroups of patients whose risk of PE may differ from the overall patient population, he noted.

“Different diagnostic strategies for PE have a variable performance in patients with differences of age, active cancer, and history of VTE,” said Dr. Pal. “However, in this study, no clear preference for one strategy over others could be established



CT scan shows radiographic evidence of pulmonary embolism (arrows).

Dr. James Heilman / Wikimedia Commons / CC-BY-SA-3.0

THRESHOLDS *continued on following page*

THRESHOLDS *continued from previous page*

for these subgroups, and clinicians should continue to follow institution-specific guidance.

“A single strategy should be adopted at each institution based on local needs and used as the standard of care until further data are available,” he said.

“The use of D-dimer to rule out PE, either with fixed threshold or age-adjusted thresholds, can be confounded in clinical settings by other comorbid conditions such as sepsis, recent surgery, and more recently, COVID-19,” he said.

“Since the findings of this study do not show a clear benefit of one diagnostic strategy over others in the analyzed subgroups of patients, further prospective head-to-head comparison among the subgroups of interest would be helpful to guide clinical decision-making,” Dr. Pal added.

YEARS-specific study supports D-dimer safety and value

A recent paper published in JAMA supported the results of the meta-analysis (2021 Dec 7. doi: 10.1001/jama.2021.20750). In that study, Yonathan Freund, MD, of Sorbonne Université, Paris, and colleagues focused on the YEARS strategy combined with age-adjusted D-dimer thresholds as a way to rule out PE in PERC-positive ED patients.

The authors of this paper randomized 18 EDs to either a protocol of intervention followed by control, or control followed by intervention. The study population included 726 patients in the intervention group and 688 in the control group.

The intervention strategy to rule out PE consisted of assessing the YEARS criteria and D-dimer testing. PE was ruled out in patients with no YEARS criteria and a D-dimer level below 1,000 ng/mL and in patients with one or more YEARS criteria and D-dimers below an age-adjusted threshold (defined as age times 10 ng/mL in patients aged 50 years and older).

The control strategy consisted of D-dimer testing for all patients with the threshold at age-adjusted levels; D-dimers above these levels prompted chest imaging.

Overall, the risk of a missed VTE at 3 months was noninferior between the groups (0.15% in the intervention group and 0.80% in the controls).

“The intervention was associated with a statistically significant reduction in chest imaging use,” the researchers wrote.

This study’s findings were limited by randomization at the center level, rather than the patient level, and the use of imaging on some patients despite negative D-dimer tests, the researchers wrote. However, their findings support those of previous studies and especially support the safety of the intervention, in an emergency medicine setting, as no PEs occurred in patients with a YEARS score of zero who underwent the intervention.

Downsides to applying algorithms to every patient explained

In an editorial accompanying the JAMA study (JAMA. 2021 Dec 7. doi: 10.1001/jama.2021.19282), Marcel Levi, MD, and Nick van Es, MD, of Amsterdam University Medical Center, emphasized the challenges of diagnosing PE given that many patients present with nonspecific clinical manifestations and without typical signs and symptoms. High-resolution CT pulmonary angiography allows for a fast and easy diagnosis in an emergency setting. However, efforts are ongoing to develop alternative strategies that avoid unnecessary scanning for potential PE patients, many of whom have alternative diagnoses such as pulmonary infections, cardiac conditions, pleural disease, or musculoskeletal problems.

On review of the JAMA study using the YEARS rule with adjusted D-dimer thresholds, the editorialists noted that the data were robust and indicated a 10% reduction in chest imaging. They also emphasized the potential to overwhelm busy clinicians with more algorithms.

“Blindly applying algorithms to every patient may be less appropriate or even undesirable in specific situations in which deviation from the rules on clinical grounds is indicated,” but a complex imaging approach may be time consuming and challenging in the acute setting, and a simple algorithm may be safe and efficient in many cases, they wrote. “From a patient perspective, a negative diagnostic algorithm for pulmonary embolism does not diminish the physician’s obligation to consider other diagnoses that explain the symptoms, for which chest CT scans may still be needed and helpful.”

The Annals of Internal Medicine study was supported by the Dutch Research Council. The JAMA study was supported by the French Health Ministry. Dr. Stals, Dr. Freund, Dr. Pal, Dr. Levi, and Dr. van Es had no financial conflicts to disclose. ■

PULMONARY MEDICINE

Idiopathic pulmonary fibrosis – a mortality predictor found?

BY JIM KLING

MDedge News

A low lymphocyte-to-monocyte ratio (LMR) is associated with worse survival in newly-diagnosed patients with idiopathic pulmonary fibrosis (IPF), according to a new retrospective, single-center analysis. Patients with both IPF and lung cancer also had a lower LMR than patients with IPF alone.

The study, published online in Respiratory Medicine (2021 Nov 23. doi: 10.1016/j.rmed.2021.106686), was conducted among 77 newly diagnosed patients, 40 end-stage IPF patients, and 17 patients with IPF and lung cancer. All received at least 1 year of antifibrotic therapy (pirfenidone or nintedanib). The researchers collected demographic and clinical data between December 2014 and December 2020.

The disease course of IPF is difficult to predict, with some patients progressing slowly, and others suffer a rapid decline to respiratory failure. Previous studies found that higher levels of monocytes are associated with higher mortality in IPF and other fibrotic lung disease, and both neutrophil-to-lymphocyte ratio (NLR) and



Dr. Herzog

LMR have been shown to predict mortality in lung cancer.

A previous study found that IPF patients had a higher NLR and a lower LMR than controls, but that research did not consider the impact of antifibrotic treatment, which may improve outcomes

PREDICTOR *continued on following page*



NASHVILLE CHEST 2022

OCTOBER 16-19

Call for Abstracts and Case Reports

Provide valuable insight into emerging medicine and clinical advancements happening in pulmonary, critical care, and sleep medicine. Submit an abstract or case report for CHEST 2022, and you could have the opportunity to:

- Share your findings with thousands of colleagues.
- Gain feedback from expert faculty.
- Collaborate with other professionals in the field.
- Be published in the prestigious journal *CHEST*®.

Submission deadline: **March 31**

LEARN MORE: chestmeeting.chestnet.org



Experimental plasma exchange shows promise for IPF flares in preliminary study

BY RICHARD MARK KIRKNER

Acute flares of idiopathic pulmonary fibrosis can have a mortality rate as high as 90% or more. But an experimental regimen that includes autoantibody reduction was found to improve survival significantly, as well as oxygen levels and walk distances, according to a preliminary study published in PLOS ONE (2021 Nov 23. doi: 10.1371/journal.pone.0260345).

“It’s a preliminary study, but it’s very exciting,” Amit Gaggar, MD, PhD, an endowed professor of medicine at the University of Alabama at Birmingham, said in an interview. “We don’t really have a treatment for acute exacerbations of pulmonary fibrosis, and the mortality is extremely high, so it’s really critical that we start thinking outside the box a little bit for therapeutics.” Dr. Gaggar isn’t affiliated with the study.

Study leader Steven R. Duncan, MD, also of UAB, acknowledged that the experimental therapy has its detractors. “There’s been a tremendous bias against the role of immunologic therapy in idiopathic fibrosis, although it seems to be lessening.”

The preliminary study treated 24 patients who had acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF) with a 19-day regimen called triple-modality autoantibody reduction. The three contributing modalities are therapeutic plasma exchange (TPE), rituximab, and intravenous immunoglobulin treatments. The standard treatment for AE-IPF consists of antibiotics and corticosteroids.

Dr. Duncan led the only other study of autoantibody reduction for AE-IPF, published in PLOS ONE in 2015. The latest preliminary study is a precursor to a National Heart, Lung, and Blood Institute-funded phase 2 randomized clinical trial, called STRIVE-IPF, currently enrolling AE-IPF patients at six sites.

In the preliminary study, 10 patients survived at least a year, an overall survival rate of 42%. Overall survival rates at 1, 3, and 6 months were 67%, 63%, and 46%. The study couldn’t identify characteristics of survivors versus nonsurvivors, although the latter had a trend toward greater initial oxygen requirements. Among the 10 patients who needed

“We don’t really have a treatment for acute exacerbations of pulmonary fibrosis, and the mortality is extremely high, so it’s really critical that we start thinking outside the box a little bit for therapeutics.”

less than 25 L/min supplemental O₂, the survival rate was 57%. In patients who needed more than 25 L/min, the survival rate was 20% ($P = .07$). Only one of five patients who needed greater than 40 L/min survived a year ($P = .36$).

After the 19-day regimen, 15 patients, or 63%, had significant drops in supplemental O₂ requirements, from an average of 15 L/min to 3 L/min ($P = .0007$). Thirteen (87%) of the patients who were taking an antifibrotic medication (either pirfenidone or nintedanib) at baseline needed less O₂ and/or had increased walking distances, compared with five who weren’t prescribed either of the agents ($P = .15$), although 1-year survival didn’t vary significantly with antifibrotic use.

“Plasma exchange rapidly gets rid of the antibodies,” he added in an interview. “It’s the basis for a number of autoantibody-mediated diseases, such as myasthenia gravis.”

While the TPE removes the B cells, they have a proclivity to re-emerge, hence the rituximab treatment, he said. IV Ig further inhibits B-cell

activity. “The IV Ig probably works in large part by feedback inhibition of the B cells that have survived the rituximab,” Dr. Duncan said.

He added that with the TPE and rituximab patients had “sometimes amazing response” but then would relapse. “Since we added IV Ig, we see far fewer relapses,” he said. “And interestingly, if they do relapse, we can salvage them by giving them this treatment again.”

The preliminary study doesn’t make clear what patients would benefit most from the triple-modality therapy, but it did provide some clues. “We found that patients who have higher levels of antibodies against epithelial cells tend to do the best, and patients who had less severe disease – that is, less disturbance of gas exchange requiring less O₂ – tend to do better,” Dr. Duncan said. The STRIVE trial should serve to identify specific biomarkers, he said.

Dr. Gaggar, a UAB professor who’s not affiliated with the study, concurred that it’s “too early to tell” which patients would benefit. “Certainly, these patients that undergo exacerbations would be of high interest,” he said, “but the potential is there that the other chronic lung diseases that have exacerbations may also benefit from this kind of therapy.”

He noted that, “In many of these studies where we limit ourselves to a single autoantibody population, we might be at the tip of iceberg,” Dr. Gaggar said.

“There might be autoantibodies generated from other cells in the lung or the body that might be also pathogenic. This is really powerful because this is a subgroup of autoantibodies, but they still had that kind of impact in this small study.”

Dr. Duncan disclosed relationships with Novartis and Tyr Pharma outside the study subject. Dr. Gaggar has no relevant disclosures. ■

PREDICTOR *continued from previous page*

(Lung. 2020 Oct;198[5]:821-7).

There has been accumulating cellular and molecular evidence that leukocyte population abnormalities are associated with IPF outcomes, but that work was more discovery based and relied on tests that aren’t readily available clinically, said Erica L. Herzog, MD, PhD, who was asked to comment on the study.

“It’s provided a lot of insight into potential new mechanisms and potential biomarkers, but their clinical utility for patients is limited. So the use of lymphocyte-to-monocyte ratios that can be obtained from a complete blood cell count, which is a test that can be done in any hospital, would really be a game-changer in terms of predictive algorithms for patients with IPF,” said Dr. Herzog, who is a professor of medicine and pathology at Yale University, New

Haven, Conn., and director of the Yale ILD Center of Excellence.

In humans, abnormalities in circulating monocytes and lymphocytes have individually been linked worse IPF outcomes. Animal studies have implicated monocyte-derived cells in lung fibrosis, but because animal studies have shown that lymphocyte populations are not required for fibrosis, more work is needed.

“I think what we’re finding is that lymphocytes probably have a regulatory role, and there’s probably a protective population and potentially a pathogenic population. Something about the balance between adaptive immunity, which is reflected by your lymphocytes, and innate immunity, which is reflected by your monocytes. Something about that balance is important for tissue homeostasis, and then when it’s disrupted or perturbed, fibrosis ensues,” said Dr. Herzog.

Newly diagnosed patients were older (mean age, 70 years) than end-stage IPF patients (mean age, 60 years) and patients with IPF and lung cancer (64 years; $P < .0001$).

Among newly diagnosed IPF patients, a receiving operating characteristic analysis before antifibrotic treatment determined a cutoff LMR value of less than 4.18, with an area under the curve of 0.67 ($P = .025$). Values below 4.18 were associated with shorter survival (hazard ratio, 6.88; $P = .027$). Patients with LMR less than 4.18 were more likely to be men (89% vs. 67%; $P = .036$), had a lower percent predicted forced vital capacity (76% vs. 87%; $P = .023$), and were more likely to die or undergo lung transplant (34% vs. 5%; $P = .009$).

A Kaplan-Meier curve illustrated a stark difference between patients with LMR of 4.18 or higher, nearly

all of whom remained alive out to almost 100 months of follow-up. Around 30% of those with LMR less than 4.18 remained alive while close to 100% of the patients with LMR below this value showed worsened outcomes. “You don’t normally see curves like that,” said Dr. Herzog.

There was no significant difference in blood cell counts and ratios at the time of IPF diagnosis and after 1 year of antifibrotic treatment, which suggests that the risk profile is independent of treatment.

Patient with IPF and lung cancer had the lowest mean LMR (2.2), followed by newly diagnosed patients (3.5), and those with end-stage disease (3.6; $P < .0001$).

The study authors reported financial relationships with various pharmaceutical companies. Dr. Herzog had no relevant financial disclosures. ■

KOSMOS HAS BEEN BENCHMARKED AND COMPARED WITH LARGER, MORE EXPENSIVE ULTRASOUND SYSTEMS FOR DAY-TO-DAY USE AT THE BEDSIDE, IN A 'SAME PATIENT, SAME USER' STUDY IN A LARGE ACUTE-CARE HOSPITAL IN EUROPE. SCAN THE QR CODE FOR THE BENCHMARK STUDY.



> echo queue



Use of Kosmos in day-to-day bedside clinical care in a large acute-care hospital in Europe is showing to reduce ordered echoes while reducing treatment optimization times*.

In a clinical validation for FDA clearance involving 600 test cases, Us2.ai's deep learning algorithms have been shown to process 23 cardiac measurements in approximately 2 minutes, a drastic reduction from current manual methods†.



Scan the QR code to view a copy of the benchmark study comparing Kosmos to larger, more expensive ultrasound systems.

*Formal studies are underway. †The overall time for complete interpretation of a case may depend on other factors such as interpreting physician and the preparation time for analysis software input files. EchoNous, Inc. © 2022 All Rights Reserved.

Heavy snoring in early pregnancy linked to increased insulin resistance

BY KRISTIN JENKINS

MDedge News

Severe maternal sleep-disordered breathing (SDB) is a known risk factor for gestational diabetes, which is commonly diagnosed in the second or third trimester of pregnancy.

Now, a new study suggests that increases in insulin resistance, a precursor for gestational diabetes, may take place as early as the first trimester of pregnancy in women with risk factors for obstructive sleep apnea (OSA), such as overweight and habitual snoring.

This finding could potentially provide physicians with a window of opportunity to improve outcomes by screening at-risk women early in pregnancy or even prior to conception, Laura Sanapo, MD, assistant professor of medicine (research) at Brown University, Providence, R.I., and colleagues wrote in *Sleep* (2022 Jan 6. doi: 10.1093/sleep/zsab281).

Brandon B. Seay, MD, comments: This paper highlights the possible utility of OSA/sleep-disordered breathing screening in patients who may not have elevated BMI, which is typically present in individuals at risk for OSA, if they show other symptoms (snoring, excessive daytime sleepiness). Early intervention with positive airway pressure therapy could possibly help decrease the risk of progressing to gestational diabetes and the detrimental effects of that on a pregnancy.

“Further studies are needed to investigate the association and its impact on the development of gestational diabetes, and to establish whether early-gestation or pregestational treatment of SDB would improve glucose metabolic outcomes in pregnancy,” they wrote.

Waiting until mid-pregnancy to screen for OSA “is too late to make significant changes in the care of these women.

By the time you diagnose gestational diabetes, the cat is out of the bag.”

“What this paper demonstrates is that the changes that predate gestational diabetes are seen much earlier in pregnancy,” senior study author Ghada Bourjeily, MD, professor of medicine at Brown University, said in an interview. Women should be screened for SDB rather than insulin resistance in early pregnancy since continuous positive airway pressure therapy (CPAP) is a highly effective intervention.

Waiting until mid-pregnancy to screen for OSA “is too late to make significant changes in the care of these women,” said Dr. Bourjeily, who is also director of research and training at the Women’s Medicine Collaborative at The Miriam Hospital in Providence. “By the time you diagnose gestational diabetes, the cat is out of the bag.”

For the study, women with early singleton preg-

nancies and risk factors for OSA such as habitual snoring and a median body mass index of at least 27 kg/m² were recruited from two prospective clinical trial studies enriched for OSA positivity. Women with a history of pregestational diabetes and those using CPAP or receiving chronic steroid therapy were excluded from the current study.

A total of 192 study participants underwent home sleep apnea test (HSAT) and homeostatic model assessment (HOMA) between 11 and 15 gestational weeks, respectively. The association between continuous measures of SDB as a respiratory-event index as well as oxygen-desaturation index and glucose metabolism parameters such as insulin resistance (HOMA-IR) were analyzed after adjusting for gestational age, maternal age, BMI, ethnicity, race, and parity.

In all, 61 women (32%) were diagnosed with OSA based on respiratory event index values greater than or equal to five events per hour. These participants were more likely to be older, to have a high BMI, and to be multipara, compared with women who didn’t have a diagnosis of OSA. Women with a diagnosis of OSA exhibited higher glucose and C-peptide values and a higher degree of insulin resistance, compared with women without OSA, the researchers found. An increase of 0.3 in HOMA-IR related to maternal SDB in early pregnancy may significantly affect glucose metabolism.

Although the findings of the current study cannot be extrapolated to women who don’t have overweight or obesity, some women with normal-range BMI (18.5-24.9) are also at increased

PREGNANCY *continued on following page*

FDA OKs new adult insomnia medicine

BY ERIK GREB

The Food and Drug Administration has approved the dual orexin receptor antagonist daridorexant (Quviviq) for the treatment of insomnia in adults, the drug’s manufacturer, Idorsia, has announced.

The FDA’s decision was based partly on a phase 3 trial of adults with moderate to severe insomnia who were randomly assigned to receive 25 or 50 mg of daridorexant or matching placebo. Daridorexant was associated with dose-dependent improvements in wake after sleep onset, total sleep time, and latency to persistent sleep.

Whereas the overall results are very positive, the improvements in daytime functioning are especially “exciting,” Thomas Roth, PhD, director of the Sleep Disorders and Research Center at Henry Ford Hos-

pital in Detroit, said in an interview.

“That’s sort of a big deal. For me, that’s the biggest deal there is,” said Dr. Roth, who was a consultant on the design of the phase 3 trial and on the interpretation of the data.

The drug will be available in doses of 25 mg and 50 mg, and the FDA has recommended that it be classified as a controlled substance. After it is scheduled by the Drug Enforcement Administration, daridorexant is expected to be made available in May.

Favorable safety profile

Insomnia is a common disorder characterized by difficulty falling asleep or staying asleep and by early-morning awakenings. Patients with insomnia often report fatigue, irritability, and difficulty with concentration. The condition can also result in significant problems with work and social activities, thus con-

tributing to anxiety or depression.

As with other dual orexin receptor antagonists, daridorexant competitively binds with both orexin receptors in the lateral hypothalamus to block the activity of orexin in a reversible way. This approach decreases the downstream action of the wake-promoting neurotransmitters that are overactive in patients with insomnia.

The phase 3 trial measured daytime functioning using the new Insomnia Daytime Symptoms and Impacts Questionnaire (IDSQ), a patient-reported outcome instrument. Daridorexant was associated with significant improvements in daytime function, particularly in sleepiness and mood.

Previous trials of other dual orexin receptor antagonists did not use the IDSQ as an outcome, so it is not possible to compare daridorex-

ant with those drugs in this respect, Dr. Roth noted. Researchers also have not conducted head-to-head trials of the drug with other dual orexin receptor antagonists.

Daridorexant also had a favorable safety profile and was not associated with rebound insomnia or withdrawal effects. The most common adverse events were headache and somnolence or fatigue.

“They had no effect on sleep stage distribution [and] they had no significant effects on sleep and breathing in people with mild to moderate sleep apnea,” said Dr. Roth, who presented the phase 3 findings at SLEEP 2020.

In addition to serving as a consultant for Idorsia on the trial design and interpretation of results, Dr. Roth has also served as a consultant for other companies that develop sleep agents. ■

OSA linked to white-matter hyperintensities

BY JIM KLING

Individuals diagnosed with obstructive sleep apnea (OSA) have higher volumes of white-matter hyperintensities (WMHs), according to a new analysis of data from the SHIP-Trend-0 cohort in Western Pomerania, Germany, which is part of the Study of Health In Pomerania. The association was true for individual measures of OSA, including apnea-hypopnea index (AHI) and oxygen desaturation index (ODI).

WMHs are often seen on MRI in older people and in patients with stroke or dementia, and they may be an indicator of cerebral small-vessel disease. They are linked to greater risk of abnormal gait, worsening balance, depression, cognitive decline, dementia, stroke, and death. Suggested mechanisms for harms from WMHs include ischemia, hypoxia, hypoperfusion, inflammation, and demyelination.

WMHs have been linked to vascular risk factors like smoking, diabetes, and hypertension. Brain pathology studies have found loss of myelin, axonal loss, and scarring close to WMHs.

Although a few studies have looked for associations between WMHs and OSA, they have yielded inconsistent results. The new work employed highly standardized data collection and more comprehensive covariate adjustment. The results, published in *JAMA Network Open* (2021 Oct 5. doi: 10.1001/jamanetworkopen.2021.28225), suggest a novel, and potentially treatable, pathological WMH mechanism, according to the authors.

“This is an important study. It has strong methodology. The automated

analysis of WMH in a large population-based cohort helps to eliminate several biases that can occur in this type of assessment. The data analysis was massive, with adequate control of all potential confounders and testing for interactions. This

“The association varies according to the degree of apnea severity, so mild OSA is probably not associated with increased WMH, while severe OSA is most likely driving most of the associations.”

generated robust results,” said Diego Z. Carvalho, MD, who was asked to comment on the findings. Dr. Carvalho is an assistant professor of neurology at the Center for Sleep Medicine at the Mayo Clinic, Rochester, Minn.

Worse apnea, worse hyperintensity

“The association varies according to the degree of apnea severity, so mild OSA is probably not associated with increased WMH, while severe OSA is most likely driving most of the associations,” said Dr. Carvalho.

If a causal mechanism were to be proven, it would “bring a stronger call for treatment of severe OSA patients, particularly those with increased risk for small-vessel disease, [such as] patients with metabolic syndrome. Likewise, patients with severe OSA would be the best candidates for therapeutic trials with

[continuous positive airway pressure] with or without possible adjunctive neuroprotective treatment for halting or slowing down WMH progression,” said Dr. Carvalho.

Stuart McCarter, MD, who is an instructor of neurology at the Center for Sleep Medicine at the Mayo Clinic, Rochester, Minn., also found the results interesting but pointed out that much more work needs to be done. “While they found a relationship between OSA as well as OSA severity and WMH despite adjusting for other known confounders, it is unlikely that it is as simple as OSA is the main causal factor for WMH, given the complex relationship between OSA, hypertension, and metabolic syndrome. However, this data does highlight the importance of considering OSA in addition to other more traditional risk factors when considering modifiable risk factors for brain aging,” said Dr. McCarter. The study cohort was mostly of White European ancestry, so more work also needs to be done in other racial groups.

The study underlines the importance of screening among individuals with cognitive impairment. “If OSA represents a modifiable risk factor for WMH and associated cognitive decline, then it would represent one of the few potentially treatable etiologies, or at least contributors of cognitive impairment,” said Dr. McCarter.

The SHIP-Trend-0 cohort is drawn from adults in Western Pomerania. The researchers analyzed data from 529 patients who had WMH and for whom intracranial volume data were available. Each member of the cohort also underwent polysomnography.

Brandon M. Seay, MD, comments: I agree with the comments by Dr. Carvalho. If OSA is a possible modifiable risk factor for developing cognitive decline in older age, then this would make it an important condition to screen, diagnose, and treat at younger ages. Further research into a possible mechanism would be very interesting, as there is no clear direct mechanism outside of OSA’s relation to metabolic syndrome, hypertension, and episodes of hypoxia.

Based on AHI criteria, 24% of the overall sample had mild OSA, 10% had moderate OSA, and 6% had severe OSA.

After adjustment for sex, age, intracranial volume, and body weight, WMH volume was associated with AHI (beta = 0.024; $P < .001$) and ODI (beta = 0.033; $P < .001$). WMH counts were also associated with AHI (beta = 0.008; $P = .01$) and ODI (beta = 0.011; $P = .02$).

The effect size increased with greater OSA severity, as measured by AHI for both WMH volume (beta = 0.312, 0.480, and 1.255 for mild, moderate, and severe OSA, respectively) and WMH count (beta = 0.129, 0.107, and 0.419). The ODI regression models showed similar associations for WMH volume (beta = 0.426, 1.030, and 1.130) and WMH count (beta = 0.141, 0.315, and 0.538).

Dr. Carvalho and Dr. McCarter disclosed no relevant financial relationships. ■

PREGNANCY *continued from previous page*

risk of glucose metabolism changes, Dr. Bourjeily pointed out. This includes those of Southeast Asian descent. “We found that the association of SDB parameters with insulin resistance was actually happening independently of BMI and other factors.”

Ideally, screening for SDB would begin prior to pregnancy, Dr. Bourjeily said. A BMI greater than 25 should be taken into account and patients asked if they snore and if so, whether it’s loud enough to wake their partner. They should also be asked about experiencing daytime sleepiness.

“Based on these answers, especially in women screened prior to pregnancy, there will be time to make the diagnosis of sleep apnea and get the patient on CPAP,” Dr. Bourjeily said.

“This is an interesting study and one of the rare ones looking at early pregnancy and some of the mechanisms that could possibly be contributing to gestational diabetes,” commented Grenye O’Malley, MD, assistant professor in the division of endocrinology, diabetes, and bone disease at the Icahn School of Medicine at Mount Sinai, New York. Dr. O’Malley was not involved in the study.

“It confirms our suspicions that there’s probably a lot of things happening earlier in pregnancy before a diagnosis of gestational diabetes. It also confirms that some of the mechanisms are probably very similar to those involved in the association between disordered sleep and the development of type 2 diabetes.”

However, it’s too early to determine whether screening for SDB and the use of CPAP will pre-

vent glycemic changes, Dr. O’Malley said in an interview. “Whenever we screen, we ask whether we have an intervention that changes outcomes and we don’t know that yet.”

Some of the symptoms of SDB are also common in early pregnancy, such as a BMI greater than 25 and daytime sleepiness, Dr. O’Malley pointed out. It was unclear whether the study participants had a propensity to develop type 2 diabetes or whether they were at risk of gestational diabetes.

This study was funded by the National Heart, Lung, and Blood Institute; the National Institute for Child Health; and the National Institute of General Medical Sciences. Dr. Bourjeily and colleagues, as well as Dr. O’Malley, reported having no potential financial conflicts of interest. ■



Challenge Yourself With CHEST SEEK™ Education



Offering a comprehensive collection of case-based questions in the pulmonary, critical care, and sleep medicine fields:

- Prepare for your ABIM exams.
- Learn more with detailed rationales written by top experts in the field.
- Earn all the CME credit and MOC points you need.
- Stay up to date throughout your career.
- Achieve bite-sized learning at your fingertips.

Test and improve your clinical skills in recall, interpretation, and problem-solving.

PRINT chestnet.org/store

DIGITAL seeklibrary.chestnet.org



CARDIOLOGY

Reassuring data on rare myocarditis after COVID-19 vaccination

BY MEGAN BROOKS

Adolescents and adults younger than age 21 who develop myocarditis after mRNA COVID-19 vaccination frequently have abnormal findings on cardiac MRI (cMRI) but most have a mild clinical course with rapid resolution of symptoms, a new study concludes.

“This study supports what we’ve been seeing. People identified and treated early and appropriately for the rare complication of COVID-19 vaccine-related myocarditis typically experienced only mild cases and short recovery times,” American Heart Association President Donald M. Lloyd-Jones, MD, said in a podcast.

“Overwhelmingly, the data continue to indicate [that] the benefits of COVID-19 vaccine far outweigh any very rare risks of adverse events from the vaccine, including myocarditis,” Dr. Lloyd-Jones added.

The study was published online Dec. 6 in *Circulation* (2021. doi: 10.1161/CIRCULATIONAHA.121.056583).

Using data from 26 pediatric medical centers across the United States and Canada, the researchers reviewed the medical records of 139 patients younger than 21 with suspected myocarditis within 1 month of receiving a COVID-19 vaccination.

“People identified and treated early and appropriately for the rare complication of COVID-19 vaccine-related myocarditis typically experienced only mild cases and short recovery times.”

They made the following key observations:

- Most patients were male (90.6%) and White (66.2%); the median age was 15.8 years.
- Suspected myocarditis occurred in 136 patients (97.8%) following mRNA vaccine, with 131 (94.2%) following the Pfizer-BioNTech vaccine; 128 cases (91.4%) occurred after the second dose.
- Symptoms started a median of 2

Jonathan Ludmir, MD, FCCP, comments: This is an important study. I think



Dr. Ludmir

it is also important to highlight some of the comparative studies demonstrating high risk of myocarditis associated

with COVID-19 compared with the COVID vaccine.

Editor’s Note: According to the CDC (www.cdc.gov/mmwr/volumes/70/wr/mm7035e5.htm): “After adjusting for patient and hospital characteristics, patients with COVID-19 during March 2020–January 2021 had, on average, 15.7 times the risk for myocarditis compared with those without COVID-19.”

- days (range 0-22 days) following vaccination administration.
- Chest pain was the most common symptom (99.3%), with fever present in 30.9% of patients and shortness of breath in 27.3%.
- Patients were treated with nonsteroidal anti-inflammatory drugs (81.3%), intravenous immunoglobulin (21.6%), glucocorticoids (21.6%), colchicine (7.9%), or no anti-inflammatory therapies (8.6%).
- Twenty-six patients (18.7%) were admitted to the intensive care unit; two received inotropic/vasoactive support; and none required extracorporeal membrane oxygenation or died.
- Median time spent in the hospital was 2 days.
- A total of 111 patients had elevated troponin I (8.12 ng/mL) and 28 had elevated troponin T (0.61 ng/mL).
- More than two-thirds (69.8%) had abnormal electrocardiograms and/or arrhythmias (seven with non-sustained ventricular tachycardia).
- Twenty-six patients (18.7%) had left ventricular ejection fraction

MYOCARDITIS continued on following page

MYOCARDITIS *continued from previous page*

less than 55% on echocardiogram; LVEF had returned to normal in the 25 who returned for follow-up.

- Seventy-five of 97 patients (77.3%) who underwent cMRI at a median of 5 days from symptom onset had abnormal findings; 74 (76.3%) had late gadolinium enhancement, 54 (55.7%) had myocardial edema, and 49 (50.5%) met Lake Louise criteria for myocarditis.

“These data suggest that most cases of suspected COVID-19 vaccine-related myocarditis in people younger than 21 are mild and resolve quickly,” corresponding author Dongngan Truong, MD, Division of Pediatric Cardiology, University of Utah and Primary Children’s Hospital, Salt Lake

City, said in a statement.

“We were very happy to see that type of recovery. However, we are awaiting further studies to better understand the long-term outcomes of patients who have had COVID-19 vaccination-related myocarditis. We also need to study the risk factors and mechanisms for this rare complication,” Dr. Truong added.

Dr. Lloyd-Jones said these findings support the AHA’s position that COVID-19 vaccines are “safe, highly effective, and fundamental to saving lives, protecting our families and communities against COVID-19, and ending the pandemic.”

The study received no funding. Dr. Truong consults for Pfizer on vaccine-associated myocarditis. A complete list of author disclosures is available with the original article. ■

NEWS FROM CHEST

In Memoriam

Edward C. Rosenow III, MD, Master FCCP

Past President (1989-1990) of the American College of Chest Physicians, leader, educator, mentor, and friend, Dr. Ed Rosenow died on December 21, 2021, in Rochester, Minnesota. He was a compassionate and humble man who believed that physicians are given a gift by being invited into a patient’s life to make a difference – a lesson that he applied and taught throughout his career.

Dr. Rosenow joined the Mayo Clinic in 1966 as a consultant in Internal Medicine (Thoracic Diseases). His distinguished career in pulmonary and critical care medicine spanned 31 years at Mayo, marked by his deep commitments to medical education and patient care. Ed’s leadership positions included President of the Mayo Clinic Staff and Chair of the Division of Pulmonary and Critical Care Medicine. He will be remembered as the ultimate educator and mentor, who influenced the lives and professions of innumerable physicians. Among his many accolades and awards at Mayo, his most cherished was the Mayo Clinic Karis (caring) Award, which is given to staff who live the Mayo Clinic Values in an extraordinary way.

Ed joined CHEST in 1968, and he went on to take his place as a remarkable and memorable leader for the organization. His multitude of honors and distinguished roles, far



Dr. Rosenow

too numerous to list here, included CHEST President, Master Fellow, Co-founder and President of The CHEST Foundation, and an Endowed Master Teacher Honor Lecture award created in his name. So many other selfless and dedicated commitments of his time and expertise are witness to his passion for fostering the development of physicians-in-training and improving patient care.

CHEST extends heartfelt condolences to Dr. Rosenow’s wife of 64 years, Connie Grahame Rosenow, the Rosenow family, and many friends and colleagues.

A personal reflection from two close colleagues and long-time friends of Dr. Rosenow will be shared in the March issue of *CHEST Physician*. ■

2022 COURSES

CHEST Global Headquarters | Glenview, IL



- MAR 11-12 | Mechanical Ventilation: Critical Care Management
- MAR 17-19 | Comprehensive Bronchoscopy With Endobronchial Ultrasound
- MAR 24-25 | Ultrasonography: Essentials in Critical Care
- APR 22-23 | Advanced Clinical Training in Pulmonary Function Testing
- APR 28-30 | Critical Skills for Critical Care: A State-of-the-Art Update and Procedures for ICU Providers
- MAY 12-13 | Advanced Critical Care Echocardiography: Image Acquisition and Interpretation
- MAY 19-20 | Therapeutic Bronchoscopy for Airway Obstruction With Cadavers
- MAY 21 | Bronchoscopy and Chest Tubes in the ICU With Cadavers
- JUN 2-4 | Difficult Airway Management
- JUN 9-10 | Ultrasonography: Essentials in Critical Care
- JUL 22-23 | Mechanical Ventilation: Critical Care Management
- AUG 5-6 | Cardiopulmonary Exercise Testing
- AUG 26-27 | **NEW!** Advanced Diagnostic Bronchoscopy for Peripheral Nodules
- SEP 8-10 | Difficult Airway Management
- SEP 15-16 | Ultrasonography: Essentials in Critical Care
- SEP 22-24 | Comprehensive Bronchoscopy With Endobronchial Ultrasound
- NOV 10-11 | Critical Care Ultrasound: Integration Into Clinical Practice
- NOV 18 | Comprehensive Pleural Procedures With Cadavers
- NOV 19 | Advanced Airway Management With Cadavers
- DEC 1-2 | Ultrasonography: Essentials in Critical Care
- DEC 9-10 | Extracorporeal Support for Respiratory and Cardiac Failure in Adults
- DEC 6, 13, 15 | Virtual Advanced Critical Care Echocardiography Board Review Course

LEARN MORE AND REGISTER
chestnet.org/simulation

NETWORKS

Get to know your new Networks' leadership

Last month, we introduced the new Networks structure. This month, we invite you to get to know your new Networks leadership. Under the new structure, previously defined steering committees are now known as Sections.

There are 22 Sections grouped under the leadership umbrella of 7 Networks. The Networks are composed of the Section chairs, vice-chairs, and members-at-large. The Council of Networks still provides oversight. This layered approach is intended to help reduce silos and support improved collaboration between groups.

We're pleased to introduce your new Network Chairs, who are dedicated to advancing and promoting the specialty areas of interest that matter to you.



Dr. Blaivas

Airway Disorders Network Chair

Allen Blaivas, DO, FCCP, is a clinical assistant professor at Rutgers University Medical School and the Medical Director, Sleep Services at VA New Jersey Health Care System. Dr. Blaivas chaired the previous Airway Disorders Network Steering Committee from 2020-2021.

Under his leadership, the group published several articles and infographics for the COVID-19 Task Force and *CHEST Physician*. His clinical research interests include obstructive sleep apnea and COPD.



Dr. Carroll

Critical Care Network Chair

Christopher Carroll, MD, FCCP, is the Medical Director, Surgical Critical Care and Research Director, Pediatric Critical Care at the Connecticut Children's Medical Center. Dr. Carroll chaired the previous Critical Care Network Steering Committee from 2019-2021 and has

been a long-time champion of the Networks and a leader in a myriad of other CHEST committees. He is passionate about using social media as a tool for education.



Dr. Restrepo

Chest Infections & Disaster Response Network Chair

Marcos Restrepo, MD, PhD, FCCP, is a professor of medicine and the Associate Program Director of the Pulmonary/Critical Care Medicine Fellowship Program at the University of Texas Health Science Center at San Antonio. He is also

an investigator and Medical Director of the

Medical Intensive Care Unit at the South Texas Veterans Health Care System. Dr. Restrepo chaired the previous Chest Infections Network Steering Committee from 2019-2021. He is also a member of the *CHEST* Journal Editorial Board for Chest Infections.



Dr. Levine

Diffuse Lung Disease & Lung Transplant Network Chair

Deborah Jo Levine, MD, MS, FCCP, is a professor of medicine and the Medical Director, Lung Transplant and Director of the Pulmonary Hypertension Center at University of Texas Health Science Center at San Antonio. Dr. Levine has been

involved with the Networks for 10 years. She chaired the Lung Transplant Network Steering Committee from 2012-2014 and was a member of the Pulmonary Vascular Disease Network Steering Committee from 2019-2021. Her interests include evaluation and therapy for antibody-mediated rejection in lung transplantation, and PH.



Dr. Bowton

Pulmonary Vascular & Cardiovascular Network Chair

David Bowton, MD, FCCP, is the Professor Emeritus, Critical Care Section, Department of Anesthesiology at Wake Forest Baptist Medical Center. He has a long history of serving the Networks. He was a member of the Critical Care Net-

work Steering Committee and chair of both the Respiratory Care Network from 2017-2019 and the Cardiovascular Medicine & Surgery Network Steering Committee from 2019-2021. He further served as member of the Executive Committee of the Council of Networks from 2017-2021. Pneumonia, clinical reasoning, and improving processes in critical care are a few of his clinical and research interests.



Dr. D'Ambrosio

Sleep Medicine Network Chair

Carolyn D'Ambrosio, MD, FCCP, is an associate professor of medicine and Vice Chief for Fellowship Training in the section of Pulmonary Critical Care at Yale School of Medicine. She served as the Women's Lung Health Network Chair from 2017-2019 and as a mem-

ber of the Sleep Medicine Network Steering Committee from 2012-2016. Dr. D'Ambrosio's current tenure as a CHEST Foundation Trustee

and Chair of the Women & Pulmonary Work Group will also help guide and inform the Network going forward.



Dr. Tanner

Thoracic Oncology & Chest Procedures Network Chair

Nichole Tanner, MD, FCCP, is a professor of medicine at Medical University of South Carolina and a pulmonologist at the Ralph H. Johnson VA Medical Center. She most recently chaired the Thoracic Oncology Network Steering Committee from 2020-2021

and served on the Executive Committee of the Council of Networks. Dr. Tanner has been active with the Thoracic Oncology group since 2015. Her academic focus is on lung cancer and translational research.

If you are interested in serving on a Network Section, keep an eye out for our annual Call for Committee Applications opening this spring.

Here are ways to stay (or get) involved with the Networks:

- Subscribe to receive the latest information on topics most important to you by joining a Network. Network membership gives you access to Network News, a bi-yearly communication from your Network chair with relevant education course offerings, key events in the CHEST community, and up-to-date information on happenings in your Network.
- Join multiple Networks, or change your affiliation any time, by logging in to your CHEST Account, and indicate your preferences on the Networks page.
- Apply for a position when the call for nominations opens. Keep an eye out soon for an announcement.
- Join a Network call. Contact the Networks staff liaison for access to the call information, available soon on the individual Network webpages.

Visit the new Network webpages at chestnet.org/networks. ■

INDEX OF ADVERTISERS

Biodesix Nodify	24
EchnoNous, Inc. Kosmos	13
GSK Nucala	2-5
Philips Company RespirTech	9

Past President's perspective

BY STEVEN Q. SIMPSON, MD, FCCP

It's January 1, 2022, as I write, and my CHEST presidency came to an end last night as the fireworks lit up the sky. With COVID-19 waxing and waning across the United States and around the world, I have been a wartime president. CHEST has not been able to do a number of the things that we would normally have done in person, including that there has not been an in-person CHEST annual meeting during my entire presidency. We have, nonetheless, achieved some important things that I will share with you.

If you're a typical CHEST member, you probably don't spend a lot of time wondering about CHEST's finances, nor should you. Nevertheless, CHEST - your organization - does have to be fiscally responsible if we desire to continue our educational and research missions, and that is the job of your Board of Regents, your presidents, and your professional staff at the CHEST headquarters. I'm happy to tell you that your organization is in healthy financial condition, in spite of a challenging economic environment and, being forced into remote, online annual meetings and board reviews for 2 years. What that means to us and to you is that we get to maintain and improve our full array of educational activities, including our annual meeting, our journal, our board reviews, our hands-on courses at the CHEST headquarters, and our web content. And, we get to accelerate our advocacy activities for our patients and for the clinical folks who care for them (us!). CHEST is primed for emerging from this pandemic stronger, because we have had to make the most of every dollar we have, and more innovative, because that's how we have done it. We are ready for new ways of interacting and for innovative new ways of delivering education, sponsoring research, fostering networking, and leading in the clinical arena of chest medicine.

During my time as CHEST President, many of us have become progressively more aware of the blatant inequities that continue in society - and, yes, even in medicine. Perhaps more than anything, it both saddens and angers me when anyone values or devalues someone else's life because of the color of their skin, who

they feel attracted to or love, the sex they were born with or their knowledge that nature gave them the wrong physical characteristics for their gender, what physical impairments they have, where they were born, where they were educated - or not, what language is their first language, or what opportunities they were presented with in their lives.



Everyone deserves the opportunity to be who and what they are and to be respected for who they are.

Dr. Simpson

Everyone deserves the opportunity to be who and what they are and to be respected for who they are, and everyone deserves the opportunity to excel. The strongest collaborations have diverse constituents with unified goals, and I want for CHEST to be among the strongest of professional collaborations. It has been deeply important to me during my presidency to champion these values, and we have worked hard to make CHEST an inclusive and diverse organization. Much remains to be done, but we did make some good progress this year.

We established a spirometry working group to look at the science around race-based adjustments for normal values, to call out if there are mistakes or omissions in that approach, and to propose the work that needs to be done to correct them. We invited the American Thoracic Society and the Canadian Thoracic Society to join us in this effort. Race is a social construct, not a physiologic principle, and some data suggest that apparent differences in physiology could actually reflect differences in socioeconomic status of study participants. In similar work, our nephrology colleagues demonstrated that apparent differences in normal glomerular filtration rate (GFR) are related to socio-economic and health care access issues; they called for labs to no longer report race-based norms for creatinine and GFR values. Our colleagues believe that race-based GFR norms have harmed patients by promoting delay in treatments aimed at preventing dialysis or by causing delays in the initiation of dialysis. In our world, asbestos companies have

argued that African American and other populations of color should receive lower asbestosis settlements on the basis that they began with lower predicted lung function and, therefore, had been less damaged by exposure to asbestos. I am very interested to see our working group's output. I think it could result in landmark changes in our evaluation and treatment of patients with lung diseases.

A very important undertaking for us this year was a top to bottom analysis of our own practices around diversity, equity, and inclusion. We started by taking lessons from the CHEST Foundation-sponsored listening tour across the nation. Many of our patients of color lack adequate access to the care they need, which informs our efforts in advocacy and health policy. We also learned that, as a profession, we have not earned the trust of our patients of color, and we must take steps to remedy that. CHEST began this effort by developing the First 5 Minutes program, which teaches all of us how to take the first moments of our interactions with patients to enhance our empathy and to establish trusting relationships with them. You will hear more about this program in the months to come.

CHEST is dedicated to ensuring that all of our members have equitable opportunities to take part in our learning activities, both as participants and as developers. Likewise, we want any member who desires to advance in our organization to have wide open opportunity to develop and use their skills. We hired a consulting firm who specializes in aiding nonprofits with their diversity, equity, and inclusion goals to

help us find our weaknesses in that area. They spent several months interviewing members at all stages of their careers and in a variety of job types, with the goal of determining what it is like to be a CHEST member of color, a woman, a member of the LGBTQIA community, or a member of any group that has been made to feel "other." We are currently working to turn their findings into concrete steps to make CHEST the most diverse and inclusive medical society possible. Finally, our consultants are helping us to ensure that the people we hire to work for our organization full time have equitable opportunities in their workplace, and that CHEST headquarters feels inclusive and is diverse for them.

COVID-19 rages on. In fact, daily case numbers at this writing are skyrocketing, higher than at any time during the pandemic, and hospitalization rates, while lower than with some of the previous waves, are following. Many of us are stressed, and in many of our ICUs, we have fewer nurses than we did at the outset of the pandemic. The CHEST COVID-19 task force continues on the job, though, with fresh content to match the current circumstances. These dedicated individuals, who I recognized with a Presidential Citation for 2021, have worked since the early days of the pandemic to scour the literature and the landscape to find the right data and the right experts to inform the topical infographics, reviews, webinars, and podcasts that are freely available to all and are posted on the CHEST website (<https://tinyurl.com/3e9cps3s>). I hope that you have availed yourself of the material

PERSPECTIVE *continued on following page*

CHEST President takes you behind the scenes with "Piece by Piece"



Dr. Schulman

CHEST President David Schulman, MD, MPH, FCCP (<https://tinyurl.com/2dsbyvbn>), begins his term by sharing new ways to make CHEST more accessible to all. Through a monthly email, Dr. Schulman will highlight key CHEST priorities and introduce you to a wide variety of members in his video and podcast series, Piece by Piece. Listen as the participants discuss their journey in medicine, their passions, and how they got involved with CHEST. Watch the first video (<https://tinyurl.com/kuxeys66>). ■

PERSPECTIVE *continued from previous page*

there, and, if not, you have missed some valuable learning opportunities. Missed them in real time, that is; they are all on the site for you to use at will. We are optimistic that someday soon, there will be less of a need for the COVID-19 task force, but the members are all ready to continue their work until that time comes.

I've highlighted just a few of the higher profile things that CHEST achieved in 2021. It would be impossible for me to cover all that CHEST has accomplished this past year. My sources tell me that during my presidency, we generated, signed on, or declined to join nearly 100 advocacy statements on topics ranging from recall of home CPAP machines to access to appropriate supplemental oxygen for patients with interstitial lung disease, to the acquisition of a nebulizer company by a tobacco company. We held successful board review sessions and repeated our all online, yet interactive, version of the CHEST annual meeting, with more than 4,000 total attendees – not as large as an in-person meeting, but not terribly far off, either. I will add that our program

chairs and their committee pivoted from a meeting in Vancouver to a meeting in Orlando to, with only 6 weeks' notice, a meeting in the ether. We are fortunate to have worked with such talented and dedicated individuals, and all of us owe them a lot for their efforts.

If, as I say, I have been a wartime president, then the worldwide viral pandemic that directly affects those of us in chest medicine has been the war. In spite of the current tsunami of cases, I am optimistic that the war ends relatively soon. CHEST will not simply return to normalcy, though. Dr. David Schulman, a brilliant and innovative educator, has taken the leadership reins of the organization, and I foresee exhilarating times ahead.

We are making it through a challenging environment, and CHEST is stronger for it. I will look forward to seeing all of you in Nashville, when we, at long last, can look one another in the eye, shake one another's hand, and enjoy the experience of the CHEST annual meeting together. And if you don't mind me asking, when you see me in Nashville, will you please do exactly that? ■

PULMONARY PERSPECTIVES®

Inhaled corticosteroids for COVID-19

BY AARON HOLLEY, MD, FCCP



Dr. Holley is Program Director, Pulmonary and Critical Care Medicine Fellowship; and Associate Professor of Medicine USU, Walter Reed National Military

Medical Center, Bethesda, Maryland. He also serves as Section Editor for Pulmonary Perspectives®.

Since the onset of the pandemic, the role for corticosteroids (CS) as a therapy for COVID-19 has evolved. Initially, there was reluctance to use oral corticosteroids (OCS) outside of COVID-19-related sepsis or acute respiratory distress syndrome (ARDS). This was in keeping with community-acquired pneumonia (CAP) guidelines (Metlay JP, et al. *Am J Respir Crit Care Med.* 2019; 200:e45-e67) and reflected concerns that OCS might worsen outcomes in viral pneumonias. At my hospital, the reluctance to use OCS was extended to inhaled corticosteroids (ICS), with early protocols advising cessation in patients with COVID-19.

In fairness, the hesitation to use ICS was short-lived and reflected attempts to provide reasonable guidance during the early pandemic data vacuum. Over time, OCS therapy has gained acceptance as a treatment for moderate-to-severe COVID-19. On top of this, the relationship between COVID-19 and asthma has proved to be complicated. It seemed intuitive that asthmatics would fair worse in the face of a highly transmissible respiratory pathogen. Data on COVID-19 and asthma provide a mixed picture, though. It also appears that the interaction varies by phenotype (Zhu Z, et al. *J Allergy Clin Immunol.* 2020;146:327-329).

Improvements with OCS and the complicated interaction between COVID-19 and asthma led some to speculate that ICS, the primary treatment for asthma, may actually be protective. There is biologic plausibility to support this concept. Generally, we've seen a variety of immunomodulators show efficacy against moderate or severe disease. Specific to ICS, data have shown a down-regulation in COVID-19 gene expression and reduction in proteins required by the virus for cell entry. This includes a reduction in the evil, much maligned ACE-2 receptor (Peters M, et al. *Am J Respir Crit Care Med.* 2020;202:83-90).

Like much with COVID-19, the initial asthma phenotype and ICS data were observational and hypothesis-generating, at best. More recently, a series of randomized trials has tested the effects of ICS in patients with

milder forms of COVID-19. The data are promising and are worth a thorough review by all physicians caring for COVID-19 outside of the hospital.

The STOIC trial (Ramakrishnan S, et al. *Lancet Respir Med.* 2021;9:763-772) randomized 146 patients to budesonide via dry powder inhaler (DPI), 800 ug twice per day (BID), versus usual care. The primary outcome was clinical deterioration, defined as presentation to acute or emergency care or need for hospitalization. There was a number of secondary outcomes designed to assess time-to-recovery, predominantly by self-report via questionnaires. The results were nothing short of spectacular. There was a significant difference in the primary outcome with a number-needed to treat (NNT) of only 8 to prevent one instance of COVID-19 deterioration. A number of the secondary outcomes reached significance, as well.

The PRINCIPLE trial, only available in preprint form (<https://tinyurl.com/mr4cah7j>), also randomized patients to budesonide via ICS vs usual care. PRINCIPLE is one of those cool, adaptive platform trials designed to evaluate multiple therapies simultaneously that have gained popularity in the pandemic era. These trials include predefined criteria for success and futility that allow treatments to be added and others to be dropped. The dosage of budesonide was identical to that in STOIC, and, again, it was delivered via DPI. By design, patients were older with co-morbidities, and there were two primary outcomes. The first was a composite of hospitalization and death, and the second was time to recovery.

The PRINCIPLE preprint is only an interim analysis. There were 751

COVID-19 *continued on following page*

Trailblazers of the Future.

YEARS
25

The CHEST Foundation 25th Anniversary Celebration continues!


Join us in 2022 as we navigate our next 25 years, and help us crush lung disease!

Every time you register for an event or make a donation, what you're really doing is funding our initiatives—programs that enable patients to get access to the care they need. Help us fulfill our mission by joining an event in honor of the CHEST Foundation 25th Anniversary.



9th Annual Irv Feldman
Texas Hold'Em Tournament
and Casino Night

Saturday, April 9, 2022



NYC Belmont Reception
and Auction

Saturday, June 11, 2022

Our events are fun. Our work is serious.

CHEST
FOUNDATION

For more information
chestfoundation.org

Optimal NIV Medicare access promotion – a hopeful way forward for users of NIV

BY NANCY COLLOP, MD, MASTER FCCP

Use of positive airway pressure (PAP) devices for treatment of sleep apnea was first described in 1981. Subsequent use of PAP devices expanded to treat patients with respiratory failure. While the treatment in this population has rapidly gained widespread use and undoubtedly has reduced morbidity and mortality in these populations, policies governing these prescriptions have not really kept up with the burgeoning need.

In 2020, Drs. Peter Gay and Robert Owens brought together a technical expert panel (TEP) to systematically review the CMS policies with an eye to remove “regulatory barriers” to improve access for these patients with the mantra: “the right device gets to the right patient at the right time.”

The panel focused on “Optimal NIV Medicare Access Promotion (ONMAP),” and members with specific expertise were recruited for five patient groups: Thoracic Restrictive Disorders (TRD), COPD, Central Sleep Apnea (CSA), Hypoventilation Syndromes (HVS), and Obstructive Sleep Apnea (OSA). Each group reviewed the current coverage, outlined the deficiencies, and suggested revisions. Herein, I will briefly highlight each group’s most important points.

TRD: The goal for this group was to bring the US standards of care closer to the rest of the world. This group advocates that the start of noninvasive ventilation (NIV) should be substantially earlier, to provide the largest improvement in disease outcome and stability. Other prominent features submitted included arterial blood gases (ABG) to not be the only form of CO₂ measurement allowed; paying for a second device if patients are using NIV continuously; qualification for a BiPAP to include if vital capacity is ≤ 80%; and,

to obtain a home mechanical ventilator, a patient must either fail BiPAP or have extreme loss of function, high pressure requirements, or need mouthpiece ventilation.

CSA: The big challenges with this diagnosis related to qualifying coverage language in the current policies, which are confusing for many providers. Additionally, these policies often deny certain PAP devices and/or oxygen therapy. The group proposed: a single definition of CSA; eliminate discussion of hypoventilation; mirror qualifying symptoms, and, continuing coverage, to the same as that for OSA treatment; and remove need



Dr. Collop

for a prior failure of BiPAP without a backup rate (BUR). The group also had specific recommendations for when oxygen therapy should be covered in patients with CSA.

COPD: This group also focused on the oxygen therapy and promoting use of devices with a BUR. Two problematic areas included the requirement that nocturnal oxygen saturation must drop to ≤ 88% for at least 5 cumulative minutes, and, that patients must begin with an S mode device (no BUR) for at least 2 months and can only then be prescribed a device with a BUR if CO₂ fails to drop. The group advocates for the removal of both, the need for a nocturnal oximetry test, and, to “try” an S mode device. The panel advocated giving the prescribing physician discretion in making this determination. The panel also provided recommendations on when a home mechanical ventilator (HMV) should be considered instead of BiPAP therapy.

HVS: Hypoventilation syndromes are a heterogeneous group of disorders with hypercapnia, defined as a PaCO₂ ≥45 mm Hg. This panel noted that the current coverage criteria are outdated and fail to recognize the spectrum of disease severity and advances in technology, which often leads to circumvention by prescribing more costly home mechanical ventilators (HMV). Consistent with the TRD group, this panel recommended acceptance of surrogate noninvasive end tidal and transcutaneous PCO₂ and venous blood gases in lieu of arterial blood gases. Additionally, they suggested no longer requiring CO₂ measures while using prescribed oxygen; eliminating the need for a sleep study to avoid delays in care for patients being discharged from the hospital; removing spirometry as a requirement; and no longer a failure of BiPAP without a BUR.

OSA: The initial purpose of examining OSA in this process was to examine when BiPAP should be utilized for treatment; however, it necessitated examination of the entire policy for PAP. The areas that were identified as needing revision included: expansion of the symptom list for patients with OSA; revising the “4 hour rule,” suggesting that 2 hours has been proven to provide benefit; eliminating the need for another sleep study to re-qualify for PAP or supplemental oxygen; and embracing telehealth as a way to improve accessibility for follow-up visits.

For details, please review the papers published in the November 2021 issue of the journal *CHEST*[®] (2021; 160[5]:1579-1990, e377-e543).

We now await what CMS will do with our recommendations and work for “the right device to the right patient at the right time.” ■

Acknowledgment: Drs. Gerald Criner, Nicholas Hill, Babak Mohklesi, Timothy Morgenthaler, and Lisa Wolfe assisted with the content.

COVID-19 continued from previous page

and 1,028 patients who received budesonide and usual care, respectively. Time to recovery was significantly shorter in the budesonide group, but budesonide failed to meet their prespecified criteria for reducing hospitalization/death. The authors noted that the composite outcome of hospitalization or death did not occur at the rates originally anticipated, presumably due to high vaccination rates. This may have led to type II error.

In a third trial published online in November (Clemency BM, et al. *JAMA Intern Med.* 2021;10.1001/jamainternmed.2021.6759), patients were randomized to 640 micrograms per day of the ICS ciclesonide. Delivery was via metered-dose inhaler (MDI) for a total duration of 30 days. Unlike the STOIC and PRINCIPLE

trials, this one wasn’t open label. It was blinded and placebo-controlled. The investigators found no difference in their primary outcome, time to resolution of symptoms. Ciclesonide did reduce the composite secondary outcome of ED visits or hospital admissions. The number needed to treat was 23.

Please indulge me while I overreact. It seems we’ve got a positive signal in all three. In the era of the Omicron variant and limited health resources, a widely available therapy that curtails symptoms and prevents acute care visits and hospitalizations could have a tremendous impact. It doesn’t require administration in a clinic and, in theory, efficacy shouldn’t be affected by future mutations of the virus.

A more sober look mutes my en-

thusiasm. First, as the authors of the ciclesonide article note, open-label trials tracking subjective outcomes via self-assessment can be prone to bias. The ciclesonide trial was double-blinded and didn’t find a difference in time to symptom resolution, only the two open-label trials did. Second, the largest study (PRINCIPLE) didn’t show a difference in escalation of care.

Given, they defined “escalation” as hospitalization or death, and vaccines and patient selection (enrolled only outpatients with mild disease) made proving a statistical reduction difficult. However, in the text they state there wasn’t an improvement in “health care services use” either. In essence, the largest trial showed no change in escalation of care, and

the trial with the best design did not show reduction in symptoms.

Although three randomized trials are enough for the inevitable meta-analysis that’ll be published soon; don’t expect it to shed much light. Combining data won’t be particularly helpful because the PRINCIPLE trial is larger than the other two combined, so its results will dominate any statistical analysis of combined data. Not to worry though – there are several more ICS COVID-19 trials underway (NCT04355637, NCT04331054, NCT04193878, NCT04330586, NCT04331054, NCT04331470, NCT04355637, NCT04356495, and NCT04381364). Providers will have to decide for themselves whether what we have so far is sufficient to change practice. ■

CRITICAL CARE COMMENTARY

The Rapid Shallow Breathing Index and liberation from mechanical ventilation

BY VATSAL TRIVEDI, MD, AND
KAREN E.A. BURNS, MD, MSC

Patients recovering from respiratory failure requiring invasive mechanical ventilation typically undergo spontaneous breathing trials (SBTs) to assess their ability to breathe on minimal (eg, pressure support [PS] with positive end-expiratory pressure [PEEP], continuous positive airway pressure [CPAP]) or no support (eg, T-piece). Once a patient has passed an SBT, they are considered liberated from the ventilator. However, a separate assessment (ability to clear and mobilize secretions, protect airway, etc) is needed to assess whether a patient is ready to be liberated from the endotracheal tube.

The Rapid Shallow Breathing Index (RSBI) is one of the parameters that can be used by clinicians to assess an individual patient's readiness to undergo an SBT. Discussion of the role of the RSBI as a tool to

predict SBT success or extubation success would be remiss without mentioning the seminal prospective observational study conducted by Yang and Tobin (Yang KL, Tobin MJ, *N Engl J Med*. 1991;324(21):1445-1450). The investigators calculated the RSBI as the ratio between frequency of breaths (f) and tidal volume in liters (Vt) using a Wright's spirometer in 100 patients. Whereas weaning success in this study was defined as the ability to maintain spontaneous ventilation for at least 24 hours after extubation, weaning failure was defined as the need (using objective and subjective criteria) to be reconnected to the ventilator at the end of a weaning trial or the need for reintubation within 24 hours of extubation. They found that an RSBI < 105 was 97% sensitive and 64% specific for predicting weaning failure, with the latter metric suggesting that there are some false positive test results. In the subgroup analysis of patients who had a duration of

mechanical ventilation of less than 8 days, the investigators found that an RSBI < 105 was 100% sensitive and 63% specific for weaning failure. While these initial results showed promise for the use of RSBI as a predictive metric, it is important to note how the primary outcome was defined and reported in this study.

Following the initial description of the performance characteristics of the RSBI, several studies were conducted to validate these findings. A meta-analysis published by Meade and colleagues found that an RSBI < 105 was associated with a small pooled positive Likelihood Ratio of 1.49 (Meade M, et al. *CHEST*. 2001;120(6 Suppl):400S-424S) for predicting extubation success. An international survey of mechanical ventilation discontinuation practices of 1,144 intensivists in six regions found that only 32.2% of respondents used an RSBI threshold of 105 or less to proceed to an SBT and 50.7% did not consider or use

the RSBI to evaluate SBT readiness (Burns KEA, et al. *Ann Am Thorac Soc*. 2018;15(4):494-502).

To assess whether the evidence base has changed over the past 20 years to support use of RSBI as a measure of extubation success, we conducted an updated meta-analysis of 48 studies (n=10,946 observations) (Trivedi V, et al. *CHEST*. 2022;161(1):97-111). In our study, we identified moderate pooled sensitivity (0.83; moderate certainty), poor specificity (0.58; moderate certainty), and a diagnostic odds ratio (DOR) (5.9) of an RSBI < 105 for predicting extubation with significant heterogeneity ($P = 95\%$). Although we noted practice variation in the timing of RSBI measurement (before, during, or at the end of SBT completion) and how RSBI measurements were made (PS vs CPAP vs T-piece), the sensitivity of pooled RSBI measurements was comparable across selected subgroups, including

VENTILATION *continued on following page*



Top **3** Reasons
Health Care Professionals
Join CHEST

- 1 Stay up-to-date professionally
- 2 Access CHEST® journal and clinical practice guidelines
- 3 Grow professionally and personally

 CHEST®

With three levels of membership, you decide the resources and benefits you want to access. Each level ensures that you stay at the forefront of patient care.

We look forward to welcoming you as an essential part of the CHEST community—join today.

Join Them chestnet.org/join

Thoracic Radiology: Imaging for Clinicians

Key Topic Areas

- Basics of thoracic imaging
- Airways
- Infections
- Diffuse lung diseases
- Solitary and multiple nodules
- Pleura/mediastinum
- Pulmonary vasculature

 CHEST®

NEW

The Only Clinical-Based Training Course in Chest Medicine

- See rare/unique cases that will deepen your knowledge base and take your thoracic imaging skills to the next level.
- Gain fuller understanding of thoracic disease states, so you can diagnose the disease and treat patients efficiently and effectively.
- Learn from CHEST's expert faculty, practicing clinicians who speak from real experience and can provide in-depth perspectives.
- Study content any time it's convenient for you.

chestnet.org/Thoracic-Radiology

VENTILATION *continued from previous page*

RSBI thresholds of <80 (sensitivity, 0.84) and RSBI measurements made on T-piece (sensitivity, 0.83) and PS (sensitivity, 0.83). Similarity, the specificity of pooled measurements was comparable among selected subgroups, including studies enrolling only patients with chronic obstructive pulmonary disease, using RSBI thresholds < 80, and including RSBI measurements made on T-piece and at the end of an SBT.

To this end, we did not identify credible subgroup effects based on patient characteristics, measurement techniques, timing of RSBI measurement, or different RSBI thresholds. Sensitivity analyses based on individual study risk of bias also did not explain the heterogeneity noted in our pooled estimates. As a standalone test, these data suggest that the RSBI has only moderate predictive ability to rule out extubation success and does not adequately predict successful extubation.

At present, considerable controversy remains regarding the best SBT technique for clinicians to utilize to conduct SBTs. A recent meta-analysis comparing all alternative SBT techniques found that trials have most often compared CPAP with T-piece SBTs and PS with T-piece SBTs. In pooled analyses, patients who underwent PS vs T-piece SBTs were equally likely to pass an SBT, but patients who underwent PS (vs T-piece) SBTs were 6% more likely to be successfully extubated, with a number needed to treat (NNT) of 22 (Burns KEA, et al. *Crit Care*. 2017;21(1):127). The authors postulated that additional PS during an SBT may not only overcome the resistance of the en-

dotracheal tube but may also compensate for clinicians "reluctance to extubate."

A large, randomized control trial conducted in 18 ICUs in Spain (n=1153) compared shorter SBTs (30 minutes) performed with PS with longer SBTs (120 minutes) performed with T-piece. The authors found an absolute increase in successful extubation of 8.2% favoring the shorter and less-demanding strategy (30-min PS SBTs) with similar reintubation rates (Subira C, et al. *JAMA*. 2019;321(22):2175-2185). These findings may, at least in part, be explained by a physiologic review that identified that SBTs conducted on PS reduced work of breathing to a larger extent than SBTs conducted on CPAP or T-piece (Sklar MC, et al. *Am J Resp Crit Care Med*. 2017;195(11):1477-1485).

The poor performance characteristics of the RSBI in predicting successful extubation suggests that additional factors may be important in predicting extubation outcome (success/failure). For example, the



Dr. Trivedi is Staff Physician, Cardiac Anesthesiology & Critical Care, University of Toronto. Dr. Burns is Staff Physician, Critical Care Medicine, University of Toronto; Clinician Scientist, Li Ka Shing Knowledge Institute; Faculty, Health Research Methods, Evidence, and Impact, McMaster University; Associate Professor, Department of Medicine, University of Toronto.

predictive ability of the RSBI may be influenced by the patient cohorts in which it was evaluated and their duration of exposure to invasive mechanical ventilation – factors that could best be explored in an individual patient meta-analysis. In addition, there was considerable variation in the criteria (subjective, objective) used to assess and report outcomes such as weaning success/failure and extubation success/failure. It is also important to acknowledge the difference between successful completion of an SBT

(signaling liberation from the ventilator) and extubation success, with the later outcome heralding successful liberation from the endotracheal tube but being hopelessly confounded by successful liberation from the ventilator. As a brief and dynamic measure of respiratory mechanics, the RSBI may be particularly well-suited to determining suitability of patients to undergo an SBT but may not be a sufficient standalone test to predict successful extubation. One potential role for the RSBI may be to aid in identifying which patients, who meet conventional permissive criteria to undergo an SBT, should be subjected to a formal SBT. This rapid assessment may be particularly helpful before conduct of a T-piece SBT, which requires assembling a T-piece circuit and disconnecting the patient from the ventilator and its alarms.

Future research should evaluate the role of the RSBI as a permissive criterion to undergo a SBT and its impact on SBT outcome (passing/failing an SBT), as opposed to extubation outcome, especially for patients who are at intermediate pretest probability of passing an SBT. ■

Editor's comment: Physicians in the intensive care unit are faced with the daily challenge of liberating patients from mechanical ventilation. We know that the longer patients receive mechanical ventilation, the higher the mortality rate. The counterpoint to this is that a failed extubation attempt describes a cohort of patients who have a very high mortality rate.

The spontaneous breathing trial (SBT) represents a commonly used assessment tool in this decision-making process. Trivedi and his colleagues provide valuable information demonstrating that the rapid shallow breathing index (RSBI) obtained during the SBT has limitations when used as a sole decision-making metric. Physicians must use careful global judgement when interpreting the results of an SBT while awaiting the outcomes of further research.

Daniel Ouellette, MD, FCCP, Section Editor

Blog, tweet, and share to expand your clinical reach

Social media is a powerful tool clinicians should be using to combat misinformation, engage with patients, and share data. In the Social Media, Digital Scholarship, Teaching Portfolios: Everything You Wanted to Know session at CHEST 2021, speakers discussed how a strong social media presence can be used on a CV to leverage academic promotions and tenure. Read more in the CHEST Daily News (<https://tinyurl.com/yc6bbu8e>) about this session. CHEST 2021 registrants can access the session recording (<https://tinyurl.com/mrvnsw>) until October 1, 2022. ■

This month in the journal CHEST®

Editor's Picks

BY PETER J. MAZZONE, MD, MPH, FCCP

Editor in Chief

Prevalence, deaths and disability-adjusted-life-years (DALYs) due to asthma and its attributable risk factors in 204 countries and territories, 1990-2019.

By Dr. S. Safiri, et al.

Cancer in cystic fibrosis: A narrative review of prevalence, risk factors, screening, and treatment challenges: Adult cystic fibrosis series.

By Dr. P. Maisonneuve, et al.



Prevalence of alpha-1 antitrypsin deficiency, self-reported behavior change, and healthcare engagement among direct-to-consumer recipients of a personalized genetic risk report.
By Dr. J. Ashenurst, et al.

Venous thromboembolism prophylaxis in critically ill adults: A systematic review and network meta-analysis.
By Dr. S. Fernando, et al.

Mass critical care surge response during COVID-19: Implementation of contingency strategies— A preliminary report of findings from the Task Force for Mass Critical Care.
By Dr. J. Dichter, et al.

INTRODUCING THE GENESTRAT NGS™ GENOMIC TEST

Expedite
time to
results.



 **genestrat**[®]
genomic test

 **genestratNGS**[™]
genomic test

 **veristrat**[®]
proteomic test

Equipping providers with biological information
that supports care decisions at any stage of lung cancer.

Discover more at biodesix.com

